

Energetic costs of cellular and therapeutic control of stochastic mtDNA populations

Hanne Hoitzing¹, Payam A. Gammage², Michal Minczuk², Iain G. Johnston^{3†}, and Nick S. Jones^{1*}

1 Department of Mathematics, Imperial College London, London, SW7 2AZ, United Kingdom

2 MRC Mitochondrial Biology Unit, University of Cambridge, Cambridge, CB2 0XY, United Kingdom

3 School of Biosciences, University of Birmingham, Birmingham, B15 2TT, United Kingdom

*nick.jones@imperial.ac.uk

†i.johnston.1@bham.ac.uk

Summary

Mitochondrial DNA (mtDNA) copy numbers fluctuate over time due to stochastic cellular dynamics. Understanding mtDNA dynamics and the accumulation of mutations is vital for understanding mitochondrial-related diseases. Here, we use stochastic modelling to derive general results for the impact of cellular control on mtDNA populations, the cost to the cell of different mtDNA states, and the optimisation of therapeutic control of mtDNA populations. We provide theoretical evidence that an increasing mtDNA variance can increase the energetic cost of maintaining a tissue, that intermediate levels of heteroplasmy can be more detrimental than homoplasmy even for a dysfunctional mutant, that heteroplasmy distribution (not mean alone) is crucial for the success of gene therapies, and that long-term rather than short intense gene therapies are more likely to beneficially impact mtDNA populations. New experiments validate our predictions on heteroplasmy dependence of therapeutic outcomes.

1 Introduction

Most human cells contain 100-10,000 copies of mitochondrial DNA (mtDNA) which are situated inside the mitochondria. The proteins encoded by mtDNA are crucial for mitochondrial functionality, and mutations in mtDNA can cause devastating diseases [1, 2, 3, 4, 5, 6]. Heteroplasmy, the proportion of mutant mtDNA molecules in a cell, has to pass a certain threshold (typically 60-95%) before any biochemical defects can be observed [7, 8, 9, 10, 11, 12, 13]. Evidence that mild mutations, that are not obviously pathological, can have physiological effects is also appearing [14]. The existence of thresholds at which mutant loads begin to have an effect has profound implications for our understanding of disease onset, drawing attention to the *variance* dynamics of the mutant fraction in cellular populations. As this variance increases more cells can be above threshold,

and thus show pathology, *even if average mutant load is unchanged.*

How cellular population fractions of mutant mtDNA change over time is not well understood. The cell exerts control on mitochondrial populations in response to changes in mtDNA copy numbers [15, 16]. Mitochondrial biogenesis and maintenance require cellular resources, and mitochondria are key sources of ATP and play other important metabolic roles: a tradeoff of bioenergetic costs and benefits is thus involved in the interaction between the cell and its mitochondria. The particular ‘effective cost’ that cellular control acts to minimise remains poorly understood: for example, both decreases [17] and increases [17, 18] in wildtype copy numbers have been observed for different mutations as the mutant load increases. Some studies suggest that mtDNA density is controlled [19, 20, 21], others that total mtDNA mass [22, 23], or mtDNA transcription rate [24] is controlled. Understanding the dynamics of mtDNA populations inside cells, and how these populations react to clinical interventions, is crucial in understanding genetic diseases [25, 26]. However, experimental tracking of mtDNA populations over time is challenging, necessitating predictive mathematical modelling to provide a quantitative understanding of these systems.

In parallel with efforts to elucidate cell physiological control, protein engineering methods to control mtDNA heteroplasmy are making fast progress. Two recently developed methods for cleaving DNA at specific sites involve zinc finger nucleases (ZFNs) and Transcription Activator-like Effector Nucleases (TALENs) [27, 28, 29, 30, 31, 32, 33], which have been re-engineered to specifically cleave mutant mtDNA [34, 35, 36, 37, 38]. Mito-TALENs have been successfully used to reduce mutant loads in cells containing disease-related mutations, but elimination of the target mutant mtDNA was not complete [39, 34]. Similarly, treating cells multiple times with mtZFNs led to near-complete elimination of mutant mtDNAs [37, 38]. Quantitative theory for these promising therapeutic technologies has not yet been developed, leaving open questions about how these tools can be optimally deployed.

In this paper, we develop theory from bottom-up bioenergetic principles which allows us to study the effects of distinct cellular mtDNA control strategies (Section 2.1), to analyse the bioenergetic cost of different mtDNA states (Section 2.2), and to combine mtDNA control and energy-based cost (Section 2.3.1) to identify optimal control strategies for the cell. Finally, we construct a model for artificial mtDNA control using recent experimental data [38] to propose optimised treatment strategies while highlighting challenges linked to heteroplasmy variance (Section 2.3.2).

	Key results presented in this paper.
I	If only one mtDNA species is controlled the variance of the controlled species reaches a constant value. When both species are controlled with equal strength their variances increase at identical rates, and, in general, the more tightly controlled species has a more slowly increasing variance (Figure 1, Section 2.1).
II	The mean energetic cost of maintaining a tissue can increase over time due to the nonlinear influence of mtDNA variance, even if the energetic demand on the tissue stays the same and mean levels of mtDNA are constant (Section 3, Eq. 3).
III	A control lacking any mutant contribution shows an exponentially increasing cost, and the effects of particular cellular control strategies are more pronounced in low copy number cells (Section 2.3.1, Figure 3A, B).
IV	Control strategies based on the energy status of the cell will often outperform control based on mtDNA copy number or sensing mtDNA mass (which would work well for deficient deletion mutants, but would be suboptimal for deficient point mutations) (Section 2.3.1, Figure 3C).
V	Even for pathological mutants, reduction of mutant mtDNA alone is not always the optimal control strategy for a cell to adopt (Section 2.3.1, Figure 4).
VI	Tissues with high mean heteroplasmy levels will generally be harder to treat with mitochondrially targeted endonucleases if the heteroplasmy variance is high, especially if this high mean level is caused by a small percentage of cells (Section 2.3.2, Figure 5D).
VII	Weak long-term rather than short intense endonuclease treatments are more likely to beneficially impact mtDNA populations (Section 2.3.2, Figure 5G, H).

Table 1: Here we present key results of the paper, which hold under the assumptions used in our models. We model mtDNA dynamics using stochastic birth-death simulations and assume: cells are heteroplasmic (containing both wildtype and mutant mtDNA molecules); birth and death rates are identical for wildtype and mutant species; the mtDNA dynamics are subject to cellular feedback control. We introduce a mitochondrial energy-based cost function; results referring to optimal controls and costs depend on the structure of this cost function which is discussed in Section 3 and Section S4.

2 Results

2.1 Control: general insights on the role of feedback control

We employ the ‘relaxed replication’ model for heteroplasmic mtDNA populations (populations in which wildtype (w) and mutant (m) mtDNA molecules co-exist). Each mtDNA molecule replicates and degrades according to Poisson processes with rates λ and μ respectively [40, 41]. Because control of biogenesis or autophagy yield similar behaviours [42], we assume that the degradation rate μ is constant and that feedback control is manifest through replication rate ($\lambda = \lambda(w, m)$). To connect with experiments, we use $\mu \approx 0.07 \text{ day}^{-1}$ corresponding to a half-life of about 10 days [43]. We consider the case where no selective difference exists between mtDNA types, although our theory is readily generalised to include such differences.

A wide range of control strategies induces similar mtDNA behaviour and admits quantitative analysis.


Whatever the quantity being controlled, in healthy cells the intuitive aim of homeostatic mtDNA control is to guarantee cell functionality by keeping the wild-type number around a particular value and within certain bounds. Many possible control strategies can be parameterised to give rise to a specific wildtype distribution; also when mutants are present the means and variances of wildtype, mutant and heteroplasmy can be nearly identical for these differing strategies up to long times (~ 80 years) (Figure 1A,B,C, Figure S1B,C,D). It is not the manner in which the controlled quantity is being controlled, but *which* quantity is controlled that is

the most important (Figure 1D).

We stress the difference between two types of average heteroplasmy (as was also mentioned in [41]): the individual cellular mean heteroplasmy $\frac{1}{n_{\text{cells}}} \sum_{\text{cells } i} \frac{m_i}{m_i + w_i}$ and the tissue homogenate heteroplasmy $(\sum_{\text{cells } i} m_i) / (\sum_{\text{cells } i} (m_i + w_i))$. The difference between individual and homogenate means is clearly seen in Figure 1C. A tissue can thus appear, when studying the homogenate heteroplasmy, to show selection for one type of mtDNA over another, whereas in fact mean cellular heteroplasmy is unaltered and both mutant and wild types have the same proliferation rates.

From here on we focus on a linear feedback control of the form $\lambda(w, m) = c_0 - c_1(w + \delta m)$, with $c_0 > 0, c_1 > 0$ and δ , corresponding to the strength of sensing of mutant mtDNA, constants. The deterministic steady states of this system, (w_{ss}, m_{ss}) are given by $(w_{ss} + \delta m_{ss}) = \frac{c_0 - \mu}{c_1}$, with μ the constant degradation rate. This line of constant $(w_{ss} + \delta m_{ss})$ forms a straight line in (w, m) space and stochastic dynamics will fluctuate around these steady state lines, with corresponding changes in heteroplasmy (Figure S1A). The parameter c_1 determines the control strength and δ allows for distinct control strengths for wildtypes and mutants.

Variance behaviour over time in mtDNA populations. Van Kampen’s system size expansion can be used to predict mtDNA variance (Table 1E), showing good agreement with stochastic simulations up to hundreds of days [42]. Applying this approximation to a general form of mtDNA control, we here find that *i) if only one species is controlled, the variance of the controlled species reaches a constant value (see also [42]), ii) when both species are controlled with equal strength*



	$\lambda(w)$	$\lambda(m)$	$\lambda(w, m)$ (including $\lambda(w + m)$)
$\sigma_w^2(t)$	$\frac{\mu}{\partial_w \lambda} (e^{2w_{ss} \partial_w \lambda t} - 1)$	$2 \frac{w_{ss}}{m_{ss}} \mu (w_{ss} + m_{ss}) t + \dots$	$\frac{2\mu m_{ss} w_{ss} (w_{ss} + m_{ss})}{(m_{ss} \partial_m \lambda + w_{ss} \partial_w \lambda)^2} (\partial_m \lambda)^2 t + \dots$
$\sigma_m^2(t)$	$2 \frac{m_{ss}}{w_{ss}} \mu (w_{ss} + m_{ss}) t + \dots$	$\frac{\mu}{\partial_m \lambda} (e^{2m_{ss} \partial_m \lambda t} - 1)$	$\frac{2\mu m_{ss} w_{ss} (w_{ss} + m_{ss})}{(m_{ss} \partial_m \lambda + w_{ss} \partial_w \lambda)^2} (\partial_w \lambda)^2 t + \dots$
$\sigma_h^2(t)$	$\frac{2m_{ss} w_{ss} \mu}{(m_{ss} + w_{ss})^3} t$		

Figure 1: **A) - C) A wide range of cellular control strategies can yield similar dynamics.** Stochastic simulations were used to compare three structurally distinct cellular controls (see legend), each reflecting a different function of the underlying sensed quantity $w + \delta m$ with $\delta = 0.5$. All controls are set to have the same wildtype mean and variance in the absence of mutants (Section S2). No marked difference in mean and variance behaviours of wildtype, mutant, and heteroplasmy were seen in simulations up to ~ 80 years (see also Section S2). Figure (C) illustrates the difference between cellular mean heteroplasmy $\sim \sum_i h_i$, which remains constant, and tissue homogenate heteroplasmy $\langle m \rangle / (\langle m \rangle + \langle w \rangle)$, which increases over time (if $\delta > 1$ it would decrease over time). **D) Control tradeoffs are required when multiple species are present.** The more strongly one species is controlled, the more control is lost over the other. Changes in variances as described by the Linear Noise Approximation (see Section S1) are shown (intermediate times). For long times, extinction of one of the species is likely and the variance of the surviving species saturates. For the control $\lambda(w, m)$ we have depicted the case in which mutants contribute less to the control than wildtypes. **E) Analytical expressions for the means and variances according to the Linear Noise Approximation.** Solutions are shown for wildtype, mutant, and heteroplasmy variances for various types of control. Dots indicate constant or exponentially decaying terms; full solutions are given in Section S1. Note that the initial rate of increase of heteroplasmy variance does not depend on the control specifics, but only on mtDNA copy number and turnover (see also [42]).

their variances increase at identical rates, iii) in general the more tightly controlled species has a more slowly increasing variance, and iv) the rate of increase of heteroplasmy variance depends, to first order, only on mtDNA copy number and turnover (as found in [42]). (Figure 1, Table 1(I)).

If a given mtDNA state (w, m) accrues a cost $C(w, m)$ to the cell (this could be an energetic cost or some other metric of tissue burden), increasing variances in w and m can lead to the mean cost $\langle C(w, m) \rangle$ changing even when mean cellular copy numbers $\langle w \rangle$, $\langle m \rangle$ remain constant (Methods), as the mean of a nonlinear function of random variables is not generally equal to the function of the mean of those variables (as seen above with cellular vs homogenate heteroplasmy). *The mean cost of maintaining a tissue may thus increase over time, even if the tissue demands stay the same and mean levels of mtDNA are constant* (Table 1(II)). However, these increases may be small and whether they are significant depends on the details of the cost function: hence the need to consider the explicit forms in the next section.

2.2 Cost: an effective mitochondrial energy-based cost function

Here, we attempt to build a cost function that assigns a cost to a given mtDNA state (w, m) and allows a general quantitative investigation of the tradeoffs in maintaining cellular mtDNA populations. The ‘true’ energy budget of a cell with a given mitochondrial population is highly complex, involving many different metabolic processes in which mitochondria are involved [44, 45, 46]. We provide a simpler description, focussing on ATP production as a central mitochondrial function, and removing kinetic details in favour of a coarse-grained representation, to provide qualitative rather than quantitative results and provide descriptions of its connection to biological observables (Methods and Section S4).

General cost function structure. Three important terms involved in the energy status of a cell are: i) the energy demand D , ii) the net energy supply S , and iii) the efficiency with which the energy is supplied. Here we define efficiency as the amount of energy that is produced per unit of resource consumed. For this study, we focus on mitochondria as the central bioenergetic actors in the cell, with wildtype and mutant mitochondria consuming resource and producing energy currency.

We express our effective cost function as:

$$C(w, m) = |D - S(w, m)| + \alpha(wr_w + mr_m) \quad (1)$$

where α is a constant, and r_i gives the rate of resource consumption of a mitochondrion of type i (w or m). The second term assigns a cost to the usage of resource. The terms in this cost function are expressed as rates: S and D then correspond to energy production (supply) and demand per unit time. This cost function assigns the lowest cost to a state that satisfies demand in the most

efficient way, and both an excess or deficit of supply are penalized.

Energy production, $S(w, m)$, is modelled as

$$S(w, m) = w(s_w(r_w) - \rho_1) + m(\epsilon_2 s_w(\epsilon_1 r_w) - \rho_1) - (w + m)\left(\frac{\rho_2 \lambda}{24 \cdot 3600} + \frac{\rho_3 \mu}{24 \cdot 3600}\right) \quad (2)$$

where $\rho_{1,2,3}$ are mitochondrial maintenance, building, and degradation costs, $s_w(r_w)$ denotes the energy production rate (per second) for a single wildtype mitochondrion given a resource consumption rate r_w (Methods, Section S4), and λ and μ denote the birth and death rates in units day^{-1} . Mutant mtDNA molecules are distinguished by the parameters $\epsilon_1, \epsilon_2 \in [0, 1]$ describing the mutant resource uptake rate (ϵ_1) and efficiency (ϵ_2) relative to that of the wildtypes. The lower the value of ϵ_1 , the lower the mutant energy output as a consequence of less resource consumption.

Despite the coarse-grained effective nature of our cost function, plausible parameterisations can be estimated (Table S1); further details on the choice of parameter values, and their biochemical interpretations are given in Section S4. We consider two different types of cost function (Methods, Section S4): the relationship between the mitochondrial resource consumption rate and energy production rate is assumed to be i) linear, or ii) saturating. The different systems will be referred to as ‘the linear output model’ or ‘the saturating output model’. The saturating output model assumes that mitochondria eventually become less efficient as the flow through their respiratory chain increases. For both these models we use two different cost function parameterisations: one for high and one for low copy number cells.

One particular parameter we will use throughout this paper is w_{opt} , the optimal (i.e. cheapest) number of wildtype mtDNA molecules in the absence of mutants. Each of our four different systems (saturating and linear, for low or high copy numbers) has its own value for w_{opt} (Table S1).

Intermediate heteroplasmies may be inefficient and resource availability can dictate the cost of mtDNA states. Figure 2 shows the value of the cost function in (w, m) space, for different mutant pathologies (different values of ϵ_1). Interestingly, it is possible to satisfy demand with only wildtype or only mutant mtDNAs, but not at certain intermediate heteroplasmies. This counter-intuitive result aligns with arguments that mixed mtDNA populations are disfavoured [14] and can be energetically explained as below (referring to Figure 2B).

Increasing heteroplasmy while keeping total copy number constant can be interpreted as replacing a wildtype mitochondrion with a mutant, leading to a tradeoff. The changed mitochondrion (from wildtype to mutant) produces less energy than before; all other mitochondria need to consume more resource to maintain a constant

total output, and so become less efficient due to output saturation. However, the changed mitochondrion itself has become more efficient because of its lower resource consumption rate. The tradeoff between these two factors depends on h itself; a more detailed discussion is given in Section S5. *The result is that intermediate heteroplasmies are the least efficient and the most expensive* (Figure 2 and S3). We note that this is only the case if i) at high respiration rates, energy production becomes less efficient, and ii) mutants consume less resource than wildtypes (perhaps through ETC deficiency), effectively making them more efficient than wildtypes (due to output saturation). A model in which mitochondrial output always increases linearly with resource consumption does not show this behaviour (Figure 2C).

2.3 Combining cost and control: comparison and optimisation of both cellular control and treatment strategies

2.3.1 Timescales and energy sensing in optimal control of mtDNA populations.

Here we compare the mean cost over time of four different plausible cellular control strategies. The first two consist of the linear feedback control discussed earlier ($\lambda(w, m) = c_0 - c_1(w + \delta m)$) with i) $\delta = 0$ (only wildtypes are sensed) and ii) $\delta = 1$ (total mtDNA copy number is controlled without differentiating between mutant and wildtype). We also consider control strategies for the cell that are optimised under our imposed cost function. We identify the optimal parameterisations that minimise steady-state cost for (iii) a linear feedback control and (iv) the relaxed replication model [40, 41].

To optimise a control, both an optimization time-scale T and a set of initial conditions are required. Here we use $T = \infty$, corresponding to the steady state limit, and a set of initial conditions with heteroplasmies in the range $h_0 \in [0, 0.2]$; we later consider finite values of T . We assume that in the absence of mutant mtDNA, each strategy is optimised and all have equal wildtype means and variances (Section S6); we compare the changes in dynamics induced by the presence of mutants.

Figure 3 shows the mean cost up to ~ 80 years resulting from stochastic simulations; cost variance, as well as mutant and wildtype dynamics were also computed (Figure S4). The relaxed replication rate control and the linear control $\lambda(w, m) = c_0 - c_1(w + \delta m)$ behave very similarly when δ and γ take their optimal values. A control with $\delta = 0$ shows an exponential increase in cost, though it still takes ~ 12 years and ~ 65 years for this control to become 10% more expensive than the others in our low and high copy number cells, respectively. We conclude that: *i) a control lacking any mutant contribution only becomes notably costly on the order of 10 years, and ii) effects of particular control strategies are*

more pronounced in low copy number cells (Table 1(III)).

We now investigate how the optimal value of mutant sensing δ , δ_{opt} , for the linear control $\lambda(w, m) = c_0 - c_1(w + \delta m)$ depends on timescale T , initial heteroplasmy h_0 and the ‘mutant pathology level’ described by parameter ϵ_1 . Biologically, this question reflects how the cell should optimise its processing of mtDNA state as the mutant load and severity changes. Intuitively, values of $\epsilon_1 \simeq 1$ have $\delta_{opt} \approx 1$: when wildtypes and mutants are equivalent, having a steady state with $w + m = w_{opt}$ is desirable.

Values for δ_{opt} were found for the linear and saturating model, with low and high initial heteroplasmy values, for $T = 100$ days (Figure 3C). Having $\delta \approx 1$ means wildtypes and mutants are fed back similarly, whereas $\delta \ll 1$ means mutants are fed back much less. For very deficient mutants (low ϵ_1), a low δ_{opt} ensures that wildtype copy number remains close to its optimal value to compensate for the mutants. Generally, as ϵ_1 decreases, δ_{opt} decreases. In the linear model δ_{opt} becomes negative for low ϵ_1 values; as mutant copy number increases, a negative δ leads to an increase in wildtype to compensate for the deficient mutants. Similar results are found for longer timescales T (Section S6).

When mitochondrial energy outputs are sensed, a deficient mutant will contribute less, so a low (or high) value for ϵ_1 is automatically associated with a low (or high) value of δ . We can see that *control strategies based on the energy status of the cell will often outperform control based on mtDNA copy number (which always has $\delta = 1$) or sensing mtDNA mass (which would work well for deficient deletion mutants, but would be suboptimal for deficient point mutations)* (Table 1(IV)).

Locally optimal control strategies map the control space of mtDNA populations. With the use of our cost function it is possible to identify *locally optimal controls*: controls that, for each state (w, m) , move the system in the direction of the largest decrease in cost (Figure 4).

When heteroplasmy is high the main priority is not always to decrease mutant copy number, but to increase wildtype copy number even if this means an increase in mutant load (region 2 in Figure 4A). It is only after wildtype copy number has sufficiently increased that the focus should be on decreasing m . At high copy numbers the optimal dynamics are to decrease all mtDNA in an evenhanded manner (region 1) rather than decreasing m at a faster rate than w . For the saturating model, we also observe a divergence point in the space of local optimal strategies, reflecting the two local cost minima (high wildtype and high mutant) observed earlier (Figure 2). Hence, there are several regions of state space where *even for pathological mutants, reduction of mutant mtDNA alone is not always the optimal control strategy* (Table 1(V)). Finally, the less pathological the mutants become (e.g. Figure 4B), the more the locally optimal control starts to resemble a linear control. In the linear




Figure 2: **Intermediate heteroplasmies can be less efficient than either wildtype or mutant homoplasmies.** A visualization of the cost function in (w, m) space is shown for the saturating and linear mitochondrial output model. Only the cost inside the demand-satisfying region is shown, for various mutant pathologies; hence, white regions correspond to states where cellular demand is not satisfied though cells may survive by, for example, increasing glycolysis, effectively reducing mitochondrial demand. All the plots in this figure are at high copy numbers, results are qualitatively similar for low copy numbers. **A)** The magenta (solid) and black (dashed) lines show the contour of the demand-satisfying region when demand is increased by 10%, or demand is increased by 50% and cellular resource availability is increased by 35%, respectively. Fluctuations increasing demand by 10% can significantly reduce the demand-satisfying region; larger fluctuations can only be handled when total cellular resource uptake rates increase. **B)** The orange line corresponds to constant total copy number; moving up along this line increases heteroplasmy. Cells in region 1 or region 3 are more efficient, and show a lower cost, than cells in region 2. **C)** The linear mitochondrial output model does not show a decreased efficiency at intermediate heteroplasmy values.




Figure 3: **A control that senses no mutations shows an exponentially increasing cost, which is most noticeable in low copy number cells.** Here we show the mean cost for the following four controls: A) the optimised ‘relaxed replication control’ $\lambda(w, m) = \frac{\mu}{w+m}(c_0(c_1 - w - \gamma_{opt}m) + w + \gamma_{opt}m)$ [40], and linear feedback controls $\lambda(w, m) = c_0 - c_1(w + \delta m)$ with B) $\delta = 0$, C) $\delta = 1$, and D) $\delta = \delta_{opt}$. The controls were initialized in steady state at $h_0 = 0.15$ and simulated for ~ 82 years (30000 repeats). Both figures used the saturating output model; the left and right figures correspond to low and high copy number cells respectively. The free parameters left in control A and D were optimised over initial conditions in the range $h \in [0, 0.2]$. Here $\epsilon_1 = 0.3$ was used, in the section below we investigate more values of ϵ_1 . Other control parameters used are given in the SI. **C)** **A control based on sensing mitochondrial energy output may be generally a good strategy.** This plot shows the optimal value of δ in the control $\lambda(w, m) = c_0 - c_1(w + \delta m)$ as a function of ϵ_1 , for the linear and saturating model and for both low ($h_0 = 0.1$, solid line) and high ($h_0 = 0.8$, dashed line) initial heteroplasmies. Here we used $T = 100$ and high copy number values for both models. The optimal mutant control contribution is broadly lower when mutants are more deficient. Similar plots for $T = 10^4$ are shown in the SI.




Figure 4: **Locally optimal controls show non-linear behaviours close to the demand-satisfying regions, but linear optimal dynamics far away from these regions.** Here we have used streamplots to visualize the locally optimal control in (w, m) space, for various parameters of ϵ_1 . At each point in the (w, m) plane, arrows show the direction of the optimal change to make to decrease cost $C(w, m)$. Regions are coloured according to the magnitude of the decrease in cost when moving in the optimal direction. Black arrows illustrate general trends in these regions. **A)** Region (1) shows that at high copy numbers, both mutant and wildtype mtDNAs should be decreased in an evenhanded manner; region (2) shows the possibility that the optimal control involves an increase in mutant copy number. Here the saturating output model is used. **B)** Like figure (A), the saturating output model is used; a higher value for the parameter ϵ_1 is used, meaning mutants are less pathological. **C)** Here the linear output model is used; the locally optimal control more closely resembles a linear control. In both (A) and (B) we see a divergence point (red asterisk) illustrating the fact that both high mutant and high wildtype states constitute local attractors of low cost (as in Figure 2).

output model, the optimal control is always quite linear (Figure 4C).

2.3.2 A parameterised model of artificial mtDNA control for disease treatment.

While the locally optimal controls identified above may not be achievable by the cell (for example, the cell may not be able to decouple biogenesis of wildtype and mutant mtDNA), genetic technology gives us the ability to artificially exploit these optimal strategies. Mitochondrially targeted Zinc Finger Nucleases (mtZFNs) [47, 48, 49, 37, 38] and mitoTALENs [34, 36] are able to produce shifts in heteroplasmy by specifically cutting mutant mtDNA; these technologies thus offer the prospect of gene therapeutic treatments for some mitochondrial diseases. Though results are promising, treatments with endonucleases are not perfect and can have substantial dose-dependent off-target effects [38]. To develop predictive quantitative theory to understand and tune the effects of these interventions, we model nuclease transfection as inducing selective increases in mtDNA degradation, on the background of the cellular feedback control described above (Methods). A fit (see Methods) of our model parameters describing strength (I_0), duration (b), and selectivity (ξ) of nuclease treatment is shown in Figure 5A, B, illustrating the ability of this simple model to capture the complex dynamics resulting from nuclease activity. For every mutant that gets cut by the endonucleases, ξ wildtypes get cut (i.e. when $\xi = 1$ there is no distinction between mutants and wildtypes, when $\xi = 0$ there is no off-target cleavage). The best-fit value for the selectivity parameter $\xi \approx 0.78$ implies a low nuclease selectivity; however, this may be due to the high mtZFN concentration that was used during the experiments (Discussion).

Nuclease treatment and a subsequent ‘recovery phase’

of cellular relaxation will have the net effect of mapping an initial heteroplasmy value h_i to a mean final heteroplasmy value, h_f . We simulated this mapping of initial to final heteroplasmy values in the presence of cellular feedback control (Figure 5), and observed that the *heteroplasmy shifts are similar in low and high mtDNA copy number cells (the variance of the shift is slightly lower for high copy number cells), and that the shift is largest for intermediate heteroplasmy values*. Interestingly, *for high h values, it is possible to end up with a higher heteroplasmy value after treatment, especially if $\xi \simeq 1$ (Figure S6)*.

Knowledge of the heteroplasmy distribution of a tissue is important in determining how efficiently the tissue can be treated.

To explore the effect of the heteroplasmy distribution on treatment efficacy, we consider three different initial h distributions with different heteroplasmy variances, but identical homogenate means. We treat these populations multiple times using the parameters fitted in the previous section, and observe the shift in heteroplasmy distribution as well as the change in heteroplasmy mean and the probability of crossing a pathogenic heteroplasmy threshold $P(h > 0.6)$ (Figure 5D, E).

High heteroplasmy variances require many cells close to the two extremes $h = 0$ and $h = 1$, which are challenging to shift. A striking reduction in treatment efficacy is predicted as heteroplasmy variance increases while mean heteroplasmy stays constant (Figure 5D, E). Threshold crossing probability (for example, $P(h > 0.6)$) also becomes harder to shift at higher heteroplasmy variance. These differences in treatment efficacy depend on the value of δ (mutant sensing) in our model: lower δ will decrease the difference in efficacies. We conclude that *tissues with a high mean heteroplasmy levels will generally be harder to treat if the heteroplasmy variance is high, especially if this high mean level is caused by a small*




Figure 5: A simple model of treating cells with mitochondrially targeted endonucleases captures experimental observations of cellular mtDNA statistics. **A, B)** Our treatment model was used to fit recent experimental data [38], good agreement was found for both deterministic and stochastic simulations; details about the fitting procedure are given in Methods. **C)** A given initial mean heteroplasmy value maps to a final mean value after a round of treatment and recovery. Stochastic simulations were performed for both low (blue, 1000) and high (green, 5000) copy number cells. The orange line denotes identity, and the purple trajectory shows the heteroplasmy shifts for multiple treatments starting at $h = 0.8$. Further details of the fitting procedure are given in Methods and Section S7. **Knowledge of the heteroplasmy distribution is important in predicting how efficiently a tissue can be treated.** **D, E)** The effect of four consecutive treatments on three different initial heteroplasmy distributions is shown; all initial distributions have identical means ($\langle h \rangle = 0.8$) but different variances (increasing from left to right). The higher the variance of the initial population, the harder to shift mean heteroplasmy values; mean values after each treatment as well as $P(h > 0.6)$ are shown more clearly in figure (E). In these simulations we assumed that every cell gets transfected. **Gentle but sustained treatments induce larger heteroplasmy shifts than hard and brief treatments.** **F)** Both the linear and saturating model show a sharp drop in the optimal treatment strength $I_{0,opt}$ as the mutants become more functional (i.e. as ϵ_1 increases). **G)** Means and variances of mutant and wildtype copy numbers were simulated during a round of treatment and recovery, using: i) fitted parameters (blue), ii) a longer treatment duration (smaller b , green) and iii) a higher selectivity (smaller ξ , magenta). The longer weaker treatment induces higher heteroplasmy shifts than the shorter stronger treatment. Not surprisingly, a higher selectivity also leads to an improved heteroplasmy shift. Note that the variance of the final values is lower for more selective treatments. Error bars show standard deviations (based on 10^4 stochastic simulations), further detailed are given in Methods and Section S7. **H)** This figure again illustrates that gentle sustained treatments lead to larger heteroplasmy shifts. Examples of treatment trajectories are shown; after a single treatment, an initial heteroplasmy of 0.8 is mapped to 0.53 (short strong treatment) or 0.39 (long weak treatment).

percentage of cells, with the strength of this effect dependent on mutant sensing (Table 1(VI)). We tested our finding that it is difficult to shift high heteroplasmy values by looking at new data from experiments focussing on the treatment of high heteroplasmy cells and find that the new results support our theory: mtZFNs were transfected into 143B cells bearing 99% m.8993T>G mtDNA, but no shift in heteroplasmy was measured 14 days post-transfection, nor at 28 days when mtDNA copy number had recovered to control level (Figure S7).

Optimal clinical interventions. We can use our parameterised theory to find optimal treatment strengths $I_{0,opt}$ for a given system. Figure 5F shows $I_{0,opt}$ as a function of ϵ_1 . Intuitively, the strongest treatment should be given to the least functional mutants, and when mutants are almost as functional as wildtypes it is preferable not to treat at all. The optimal treatment strength drops rather sharply as ϵ_1 increases, and does so sooner for the saturating model. This last observation may be because at some point reducing heteroplasmy becomes more expensive as can be seen in Figure 2B. Optimal treatment strengths for longer treatments (higher b) show similar qualitative behaviour.

Figure 5G shows, using the identified values for $I_{0,opt}$, the trajectories in (w, m) space throughout a single treatment and recovery phase; we used $\epsilon_1 = 0.3$ and the corresponding cost heatmap is also shown. The three trajectories shown correspond to: i) a short and strong treatment (using the fitted parameter values), ii) a long and weak treatment, and iii) a short but more selective treatment. It can be seen that *treating longer but weaker results in a lower final heteroplasmy value than treating short and strong*. A weaker treatment also reduces the chance of a cell losing all its mtDNA molecules. A more selective treatment also leads to larger heteroplasmy shifts. The difference in treatment results for long compared to short treatments is also illustrated in Figure 5H. We note that in finding $I_{0,opt}$, we initialized all cells in the same steady state. When a distributions of initial states is used, the variance that is now present is likely to affect the optimal treatment strength.

3 Methods

Expected cost per unit time. Let the cost per unit time of state (w, m) be denoted by Λ , and the cost corresponding to the steady state (w_{ss}, m_{ss}) by $\bar{\Lambda}$. Even if steady state copy numbers are constant over time (i.e. the mean values of w and m are always equal to w_{ss} and m_{ss}) the mean cost per unit time is generally not equal to $\bar{\Lambda}$. By performing a Taylor expansion, the mean cost per unit time can be written as follows:

$$E[\Lambda](t) \approx \bar{\Lambda} + \frac{1}{2} \left(\text{var}(w(t)) \frac{\partial^2 \Lambda}{\partial w^2} + \text{var}(m(t)) \frac{\partial^2 \Lambda}{\partial m^2} + 2\text{cov}(w(t), m(t)) \frac{\partial^2 \Lambda}{\partial w \partial m} \right) \quad (3)$$

where $E[\Lambda](t)$ is the expected cost per unit time given that the trajectory starts in state (w_{ss}, m_{ss}) , and all partial derivatives are evaluated at steady state.

Cost function structure. We assume that the net energy supply per unit time in a state (w, m) , called $S(w, m)$, involves the following four terms: (i) the *energy output* per unit time (s_i) produced by the mitochondria; (ii) a *maintenance cost* per unit time (ρ_1) to maintain the mitochondria, as their presence imposes some energetic cost (e.g. mRNA and protein synthesis); (iii) a *building cost* (ρ_2) for the biogenesis of new mitochondria; and (iv) a *degradation cost* (ρ_3) to degrade mitochondria. We will assume that every mtDNA molecule is associated to a particular amount of mitochondrial volume which we refer to as a ‘mitochondrion’ (Section S4).

At any time, mitochondria experience a certain energy demand and to meet this demand they need to have a certain resource consumption rate r_i (where $i = w, m$ refers to wildtype or mutant). Here we use the term ‘resource’ as an amalgamation of the substrates used for the oxidation system. We need to specify the relationship between the power supply (s_i) and the rate of resources consumed (r_i) by mitochondria. We use two different models $s_i(r_i)$ which are justified in the SI:

$$s_w(r_w) = \phi(r_w - \beta) \quad (4)$$

$$s_w(r_w) = 2 \frac{s_{max}}{1 + e^{-kr_w}} - 1.1s_{max}$$

where ϕ , β , k and s_{max} are constants respectively describing the mitochondrial efficiency, a basal proton leak-like term, the saturation rate of the efficiency, and the maximum energy production rate (Section S4).

We assume that pathological mutants can have a deficient electron transport chain (which may support a smaller flux leading to a lower resource consumption rate for mutants and therefore a lower ATP production rate) and a lower energy production efficiency:

$$s_m(r_m) = \epsilon_2 s_w(\epsilon_1 r_w) \quad (5)$$

Here, $\epsilon_1, \epsilon_2 \in [0, 1]$ describe the mutant resource uptake rate and the mutant energy production efficiency relative

to that of a wildtype, respectively. In the main text we set $\epsilon_2 = 1$; other values of ϵ_2 are discussed in Section S4.7.

The mitochondrial maintenance cost is denoted by ρ_1 and corresponds to the energetic cost required to maintain the mitochondrion that contains the mtDNA. This energetic costs involves factors like the synthesis and degradation of mitochondrial proteins and enzymes. We assume the maintenance cost is the same for wildtype and mutant mitochondria (though for some mutations this is quite possibly not the case). The net energy supply per unit time, $S(w, m)$, then follows as Equation 2.

To determine the value of r_w for a given state (w, m) , we first check whether the demand D (which we assume is a constant) can be satisfied in this state. If it can, we set equation (2) equal to D and solve for r_w , i.e. we assume that if possible, the mitochondria will exactly satisfy demand. It may, however, not be possible to satisfy demand, which can be because of two reasons: i) there are not enough mitochondria present to produce enough energy, or ii) there is not enough resource available to meet demand. In the former case, we set $r_w = r_{max}$; the mitochondria work as hard as possible to keep their energy output closest to demand. In the latter case, we assume that the total available amount of resource, R (which we consider to be constant), is shared equally between the mitochondria: $r_w = \frac{R}{w + \epsilon_1 m}$. Cellular energy demand will naturally fluctuate over time, and because of excess capacity of mitochondria [50], there is no need to immediately increase mitochondrial biogenesis. In our model, a given state (w, m) may be able to satisfy a range of demands by changing its resource uptake rate. Further details of the cost function are given in the SI.

The parameters used in our cost function are summarized in Table S1, a discussion of the parameter values is also provided in the SI. Despite our model being simple, most parameters are biologically interpretable.

Modelling control through mitochondrially targeted endonucleases. Experimentally, cells are transfected with two mtZFN monomers: one which binds selectively to mutant mtDNAs, and one that binds mutants and wildtypes with equal strength [49]. We simplify this picture by assuming an ‘effective’ mtZFN pool and use $[ZFN]$ to denote its concentration. The increase in mtDNA degradation rate is then assumed to be proportional to $[ZFN]$.

Nucleases are imported into the cell and then degrade over time, meaning that their concentration in the cell (and in the mitochondria) may be approximated by an Immigration-Death model. In the recent experiments [38], nucleases are expressed for short times which means that the immigration rate should be time-dependent and decreasing. This leads us to the following equation:

$$\frac{d[ZFN](t)}{dt} = I(t) - \mu_z [ZFN](t) \quad (6)$$

where $I(t)$ and μ_z are the immigration and death rates

of the effective mtZFN pool, respectively. The immigration rate will increase sharply at the start of the treatment after which it decreases over time, and we have chosen to model $I(t)$ as an exponentially decaying function, $I(t) = I_0 e^{-bt}$, where I_0 is the initial rate right after the treatment is applied and b is a constant describing the duration of the treatment. The mtZFN concentration now becomes

$$[ZFN](t) = \frac{I_0}{\mu_z - b} (e^{-bt} - e^{-\mu_z t}) \quad (7)$$

which is shown for various parameter values in Figure S6A. The mtDNA death rates at a time t after a treatment are then given by

$$\begin{aligned} \mu_m &= \mu + \frac{I_0}{\mu_z - b} (e^{-bt} - e^{-\mu_z t}) \\ \mu_w &= \mu + \xi \frac{I_0}{\mu_z - b} (e^{-bt} - e^{-\mu_z t}) \end{aligned} \quad (8)$$

where μ denotes the normal baseline mtDNA degradation rate, $0 < \xi < 1$ indicates how selective the treatment is (if $\xi = 1$ no distinction is made between w and m , if $\xi = 0$ no extra wildtype cleavage occurs during treatment).

To fit our model to recently obtained experimental data [38] we need to include the cellular feedback control which makes sure that copy number returns to its original value after the treatment. We will use $\lambda(w, m) = c_0 - c_1(w + \delta m)$ to model the feedback, and we assume $\delta = 1$ because no significant changes in total mtDNA copy numbers were seen after treatments. We fitted the parameters I_0, b, ξ and c_1 . Because mtDNA copy number in the cells used in the experiment is not known, we use both low (1000) and high (5000) initial copy numbers and fit our parameters for both cases (the value of c_0 is set such that steady state copy numbers are 1000 or 5000). The obtained parameter fits are: $(I_0, b, \xi, c_1) \approx (38, 12, 0.76, 3 \times 10^{-4})$ and $(I_0, b, \xi, c_1) \approx (40, 12, 0.76, 5 \times 10^{-5})$ for cells with initial copy numbers 1000 and 5000, respectively. For the mtZFN degradation rate we used a half-life of 1 day, to roughly match the experimental observation that almost no mtZFN was present 4 days post-transfection (with a half-life of 1 day, the size of an exponentially decaying population will be about 6% of the initial size).

Shifting heteroplasmy in 143B cells bearing 99% m.899T>G mtDNA All methods used are as described in [37], more details are provided in Section S7.

4 Discussion

In this work, we have built a quantitative theory bridging stochastic optimal control, costs of mtDNA populations, and gene therapies. Our results contribute to a growing body of evidence [51, 52, 53, 54] that the variance of mtDNA populations has important physiological and therapeutic implications independently of mean heteroplasmy, and underline that stochastic theory is required to understand this biologically and medically important quantity. We compared different cellular strategies of regulating the number of mtDNA molecules, by studying the means and variance of the mutant and wildtype populations. We found that there exists a trade-off between controlling one species, or controlling the other. Heterogeneity in sensing may thus account for the large variety of mutant dynamics seen between different mutations and across different tissues. We introduced a mitochondrial energy-based cost function enabling us to compare distinct control mechanisms and found that a control based on the energetic status of the cell forms a good strategy in many situations. Recent experimental data [38] was used to fit a therapeutic treatment model in which cells are transfected with mitochondrially targeted endonucleases, with new experiments validating this theory. We showed that long gentle treatments induce higher heteroplasmy shifts than brief strong treatments, and that tissues with high heteroplasmy variances can be particularly hard to treat.

If the parameter δ is low, i.e. mutants are sensed less, mutant copy numbers at high heteroplasmy levels will be higher than wildtype copy numbers at low heteroplasmy levels. Experimentally it has been observed that heteroplasmic cells can have total mtDNA copy number values that are 5-17-fold higher than cells homoplasmic in wildtype [55, 56, 57, 58]. The cell has somehow allowed these mutants to expand, which may mean that they are less tightly controlled; Controls based on total energy output or mtDNA mass (which can result in $\delta < 1$) may lead to such behaviours. A control on mtDNA mass could explain why deletion mutants are often seen to expand [59, 60] and would also predict normal copy number levels in cells harbouring mtDNA point mutations. Recently, it was found that samples with mtDNA indels had very high mtDNA copy number levels, but single nucleotide variants did not [61]. The cellular control mechanism could also be a mixture of copy number control, mtDNA mass control and energy sensing, meaning that mutations with different functionalities and masses all have different values for δ and expand to different extents.

We showed that heteroplasmy distributions in cell populations can provide important information about the possibility of successfully treating these cells. A tissue may be harder to treat if its high mean heteroplasmy level is caused by a small percentage of dysfunctional cells; these cells may also be hard to target using gene therapy if the transduction efficiency is low. Experimen-

tal values of mean homogenate heteroplasmy in heart tissue of patients with the 3243A>G mutation are roughly around 0.8, though ranges can be large [62, 63, 64, 65]. Muscle tissue often shows mosaic structures, with deficient patches of cells adjacent to healthy cells. These examples show that it may be that, at least in some cases, high mean levels are indeed caused by a relatively low percentage of cells, meaning that there are still a lot of challenges ahead for efficiently treating these tissues.

One of the features of our cost function is that resource limitations play an important role in shaping the cost landscape. There are indications that cellular NAD levels are limiting, and that a sufficient supply of NAD to mitochondria becomes critical [66, 67, 68, 69]. An increase of intracellular NAD can lead to an increase in oxygen consumption and ATP production [69] indicating that resource limitation may, at least in some cases, be a genuine constraint. Adding various kinds of resources can significantly change mitochondrial basal respiration rate [70, 71, 72].

We found that, under our model, it is more optimal to sense mutants to a lesser extent if the mutants have a lower energy output. In this way, their presence has little influence on wildtype copy number dynamics which then allows the wildtype mtDNA molecules to remain close to their ‘natural’ (and assumed to be close to optimal) levels. This makes a control directly based on the energetic status of the cell a good strategy.

If two different mtDNA types coexist in a cell and one type is more leaky (i.e. less efficient), then this leaky type will tend to produce less energy which could lead to a lower value for δ . Cells homoplasmic in the leaky type will then have higher mtDNA copy numbers than cells homoplasmic in the other mtDNA type (see also [73]). Reactive Oxygen Species (ROS) can damage the mitochondrial membrane and increase the amount of leak, making the mitochondria less efficient. It has indeed been suggested that increased ROS production by mutant mtDNA molecules is the reason why cells harbouring these mutations have increased mtDNA copy numbers [74]. It could also be that the increase in mtDNA copy number is due to higher numbers of wildtype mtDNA to compensate for the dysfunctional mutants. Further measurements of mutant as well as wildtype copy number values for different types of mutants, together with their energetic functionality and ROS production rates, are helpful for improving our understanding of the cell’s control mechanisms.

In modelling gene therapies, our fit to endonuclease data yielded a high off-target cutting estimate, $\xi = 0.76$, which may be a result of the high nuclease concentration in experiments: a lower mtZFN concentration could result in a lower ξ and lead to better results, as was observed experimentally [38]. If the parameter ξ is a function of the treatment strength I_0 , the values for $I_{0,opt}$ we found in Figure 5F will be different. Further work on the relationship between I_0 and ξ will elucidate more clearly

the trade-off between treating with a high strength and cleaving more mutants in the process, and having a high selectivity and therefore low off-target cleavage.

Like any other model, our models have a defined range of applicability. A key baseline assumption was using identical replication and degradation rates for mutants and wildtypes. Various possibilities of distinct rates have been offered in the literature, including faster mutant replication rates [75, 76, 77, 78, 56, 24] and lower mutant degradation rates [79], mainly to explain mutant expansion seen in several tissues. A recent computational model [24] suggested that introducing feedback control on ATP levels, with mutant mtDNAs having a deficient feedback loop, might account for experimental data regarding mutant accumulations. There are also reasons to believe that mutants might be degraded faster, especially if they are dysfunctional, through the mechanisms of quality control [80, 81]. Including such differences, and other features including *de novo* mutations, degradation control, and cell divisions [82, 52, 42, 83], constitute natural extensions to our theory.

Including these difference in turnover rates, and studying their effects on optimal clinical treatment strategies, provides an interesting future direction of studies. We did not include any cell divisions in our models, meaning that our results are mainly applicable to post-mitotic cells, though cellular division can readily be included (as in, for example, [82] which includes cell divisions during development). Other potential ways in which to develop our models further are including *de novo* mutations, considering the effect of an extra mutant cost (caused by e.g. ROS production), and including control in the degradation rate. However, the wide set of general insights and biological and therapeutic predictions that emerge even from our simple model suggest that ‘cost-and-control’ modelling of mitochondrial populations is a valuable theoretical approach to reason about these complex and vital systems that remain experimentally hard to address.

5 Acknowledgments

We thank Juvid Aryaman and Tom McGrath for useful discussions. The authors declare that there is no conflict of interest regarding the publication of this article.

References

- [1] Laar, V. S. V. and Berman, S. B. Mitochondrial dynamics in parkinson’s disease. *Exp Neurol* **218**(2), 247 – 256 (2009).
- [2] Liesa, M., Palacín, M., and Zorzano, A. Mitochondrial dynamics in mammalian health and disease. *Physiol Rev* **89**(3), 799–845 (2009).
- [3] Grandemange, S., Herzig, S., and Martinou, J.-C. Mitochondrial dynamics and cancer. *Semin Cancer Biol* **19**(1), 50–56 (2009).
- [4] Zhu, X., Perry, G., Smith, M. A., and Wang, X. Abnormal mitochondrial dynamics in the pathogenesis of alzheimer’s disease. *J Alzheimers Dis* **33**, S253–S262 (2013).
- [5] Chan, D. C. Fusion and fission: Interlinked processes critical for mitochondrial health. *Annu Rev Genet* **46**(1), 265–287 (2012).
- [6] Chen, H. and Chan, D. C. Mitochondrial dynamics - fusion, fission, movement, and mitophagy - in neurodegenerative diseases. *Hum Mol Genet* **18**(R2), R169–R176 (2009).
- [7] Rossignol, R., Faustin, B., Rocher, C., Malgat, M., Mazat, J.-P., and Letellier, T. Mitochondrial threshold effects. *Biochemical Journal* **370**(3), 751–762 (2003).
- [8] Attardi, G., Yoneda, M., and Chomyn, A. Complementation and segregation behavior of disease-causing mitochondrial DNA mutations in cellular model systems. *Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease* **1271**(1), 241–248 (1995).
- [9] Boulet, L., Karpati, G., and Shoubridge, E. Distribution and threshold expression of the tRNA (Lys) mutation in skeletal muscle of patients with myoclonic epilepsy and ragged-red fibers (MERRF). *American journal of human genetics* **51**(6), 1187 (1992).
- [10] Nakada, K., Inoue, K., Ono, T., Isobe, K., Ogura, A., Goto, Y.-i., Nonaka, I., and Hayashi, J.-I. Inter-mitochondrial complementation: mitochondria-specific system preventing mice from expression of disease phenotypes by mutant mtDNA. *Nature medicine* **7**(8), 934–940 (2001).
- [11] Moraes, C. T. and Schon, E. A. [44] detection and analysis of mitochondrial DNA and RNA in muscle by in situ hybridization and single-fiber pcr. *Methods in enzymology* **264**, 522–540 (1996).
- [12] Sciacco, M., Bonilla, E., Schon, E. A., DiMauro, S., and Moraes, C. T. Distribution of wild-type and common deletion forms of mtDNA in normal and respiration-deficient muscle fibers from patients with mitochondrial myopathy. *Human Molecular Genetics* **3**(1), 13–19 (1994).
- [13] Russell, O. and Turnbull, D. Mitochondrial DNA diseasemolecular insights and potential routes to a cure. *Experimental cell research* **325**(1), 38–43 (2014).
- [14] Sharpley, M. S., Marciniak, C., Eckel-Mahan, K., McManus, M., Crimi, M., Waymire, K., Lin, C. S., Masubuchi, S., Friend, N., Koike, M., et al. Heteroplasmy of mouse mtDNA is genetically unstable and results in altered behavior and cognition. *Cell* **151**(2), 333–343 (2012).
- [15] Montier, L. L. C., Deng, J. J., and Bai, Y. Number matters: control of mammalian mitochondrial DNA copy number. *Journal of Genetics and Genomics* **36**(3), 125–131 (2009).
- [16] Kotiadis, V. N., Duchon, M. R., and Osellame, L. D. Mitochondrial quality control and communications with the nucleus are important in maintaining mitochondrial function and cell health. *Biochimica et Biophysica Acta (BBA)-General Subjects* **1840**(4), 1254–1265 (2014).

- [17] Durham, S. E., Samuels, D. C., Cree, L. M., and Chinnery, P. F. Normal levels of wild-type mitochondrial DNA maintain cytochrome c oxidase activity for two pathogenic mitochondrial DNA mutations but not for m. 3243a g. *The American Journal of Human Genetics* **81**(1), 189–195 (2007).
- [18] Gitschlag, B. L., Kirby, C. S., Samuels, D. C., Gangula, R. D., Mallal, S. A., and Patel, M. R. Homeostatic responses regulate selfish mitochondrial genome dynamics in *c. elegans*. *bioRxiv*, 050930 (2016).
- [19] Posakony, J. W., England, J. M., and Attardi, G. Mitochondrial growth and division during the cell cycle in hela cells. *The Journal of cell biology* **74**(2), 468–491 (1977).
- [20] Jajoo, R., Jung, Y., Huh, D., Viana, M. P., Rafelski, S. M., Springer, M., and Paulsson, J. Accurate concentration control of mitochondria and nucleoids. *Science* **351**(6269), 169–172 (2016).
- [21] Otten, A. B., Theunissen, T. E., Derhaag, J. G., Lambrichts, E. H., Boesten, I. B., Winandy, M., van Montfort, A. P., Tarbashevich, K., Raz, E., Gerards, M., et al. Differences in strength and timing of the mtDNA bottleneck between zebrafish germline and non-germline cells. *Cell Reports* **16**(3), 622–630 (2016).
- [22] Tang, Y., Schon, E. A., Wilichowski, E., Vazquez-Memije, M. E., Davidson, E., and King, M. P. Rearrangements of human mitochondrial DNA (mtDNA): new insights into the regulation of mtDNA copy number and gene expression. *Molecular biology of the cell* **11**(4), 1471–1485 (2000).
- [23] Diaz, F., Bayona-Bafaluy, M. P., Rana, M., Mora, M., Hao, H., and Moraes, C. T. Human mitochondrial DNA with large deletions repopulates organelles faster than full-length genomes under relaxed copy number control. *Nucleic acids research* **30**(21), 4626–4633 (2002).
- [24] Kowald, A. and Kirkwood, T. B. Transcription could be the key to the selection advantage of mitochondrial deletion mutants in aging. *Proceedings of the National Academy of Sciences* **111**(8), 2972–2977 (2014).
- [25] Burgstaller, J. P., Johnston, I. G., and Poulton, J. Mitochondrial dna disease and developmental implications for reproductive strategies. *Molecular human reproduction* **21**(1), 11–22 (2015).
- [26] Røyrvik, E., Burgstaller, J. P., and Johnston, I. G. mtDNA diversity in human populations highlights the merit of haplotype matching in gene therapies. *Molecular Human Reproduction* **22**(11), 809–817 (2016).
- [27] Kim, Y.-G., Cha, J., and Chandrasegaran, S. Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain. *Proceedings of the National Academy of Sciences* **93**(3), 1156–1160 (1996).
- [28] Urnov, F. D., Miller, J. C., Lee, Y.-L., Beausejour, C. M., Rock, J. M., Augustus, S., Jamieson, A. C., Porteus, M. H., Gregory, P. D., and Holmes, M. C. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. *Nature* **435**(7042), 646–651 (2005).
- [29] Bibikova, M., Golic, M., Golic, K. G., and Carroll, D. Targeted chromosomal cleavage and mutagenesis in drosophila using zinc-finger nucleases. *Genetics* **161**(3), 1169–1175 (2002).
- [30] Christian, M., Cermak, T., Doyle, E. L., Schmidt, C., Zhang, F., Hummel, A., Bogdanove, A. J., and Voytas, D. F. Targeting dna double-strand breaks with tal effector nucleases. *Genetics* **186**(2), 757–761 (2010).
- [31] Li, T., Huang, S., Zhao, X., Wright, D. A., Carpenter, S., Spalding, M. H., Weeks, D. P., and Yang, B. Modularly assembled designer tal effector nucleases for targeted gene knockout and gene replacement in eukaryotes. *Nucleic acids research*, gkr188 (2011).
- [32] Miller, J. C., Tan, S., Qiao, G., Barlow, K. A., Wang, J., Xia, D. F., Meng, X., Paschon, D. E., Leung, E., Hinkley, S. J., et al. A TALE nuclease architecture for efficient genome editing. *Nature biotechnology* **29**(2), 143–148 (2011).
- [33] Joung, J. K. and Sander, J. D. TALENs: a widely applicable technology for targeted genome editing. *Nature reviews Molecular cell biology* **14**(1), 49–55 (2013).
- [34] Bacman, S. R., Williams, S. L., Pinto, M., Peralta, S., and Moraes, C. T. Specific elimination of mutant mitochondrial genomes in patient-derived cells by mitoTALENs. *Nature Medicine* **19**(9), 1111–1113 (2013).
- [35] Reddy, P., Ocampo, A., Suzuki, K., Luo, J., Bacman, S. R., Williams, S. L., Sugawara, A., Okamura, D., Tsunekawa, Y., Wu, J., Lam, D., Xiong, X., Montserrat, N., Esteban, C. R., Liu, G.-H., Sancho-Martinez, I., Manau, D., Civico, S., Cardellach, F., del Mar OCallaghan, M., Campistol, J., Zhao, H., Campistol, J. M., Moraes, C. T., and Belmonte, J. C. I. Selective elimination of mitochondrial mutations in the germline by genome editing. *Cell* **161**(3), 459 – 469 (2015).
- [36] Bacman, S. R., Williams, S. L., Pinto, M., and Moraes, C. T. The use of mitochondria-targeted endonucleases to manipulate mtDNA. *Methods in enzymology* **547**, 373 (2014).
- [37] Gammage, P. A., Van Haute, L., and Minczuk, M. Engineered mtZFNs for manipulation of human mitochondrial DNA heteroplasmy. *Mitochondrial DNA: Methods and Protocols*, 145–162 (2016).
- [38] Gammage, P. A., Gaude, E., Van Haute, L., Rebelo-Guiomar, P., Jackson, C. B., Rorbach, J., Pekalski, M. L., Robinson, A. J., Charpentier, M., Concordet, J.-P., et al. Near-complete elimination of mutant mtDNA by iterative or dynamic dose-controlled treatment with mtZFNs. *Nucleic Acids Research*, 7804–7816 (2016).
- [39] Hashimoto, M., Bacman, S. R., Peralta, S., Falk, M. J., Chomyn, A., Chan, D. C., Williams, L. S., and Moraes, C. T. Mitotalen: A general approach to reduce mutant mtDNA loads and restore oxidative phosphorylation function in mitochondrial diseases. *Molecular Therapy* (2015).
- [40] Chinnery, P. F. and Samuels, D. C. Relaxed replication of mtDNA: a model with implications for the expression of disease. *The American Journal of Human Genetics* **64**(4), 1158–1165 (1999).
- [41] Capps, G. J., Samuels, D. C., and Chinnery, P. F. A model of the nuclear control of mitochondrial DNA replication. *Journal of theoretical biology* **221**(4), 565–583 (2003).

- [42] Johnston, I. G. and Jones, N. S. Evolution of cell-to-cell variability in stochastic, controlled, heteroplasmic mtDNA populations. *The American Journal of Human Genetics* **99**(5), 1150–1162 (2016).
- [43] Gross, N. J., Getz, G. S., and Rabinowitz, M. Apparent turnover of mitochondrial deoxyribonucleic acid and mitochondrial phospholipids in the tissues of the rat. *Journal of Biological Chemistry* **244**(6), 1552–1562 (1969).
- [44] Lill, R., Hoffmann, B., Molik, S., Pierik, A. J., Rietzschel, N., Stehling, O., Uzarska, M. A., Weber, H., Wilbrecht, C., and Mühlenhoff, U. The role of mitochondria in cellular iron–sulfur protein biogenesis and iron metabolism. *Biochimica et Biophysica Acta (BBA)-Molecular Cell Research* **1823**(9), 1491–1508 (2012).
- [45] Wang, C. and Youle, R. J. The role of mitochondria in apoptosis. *Annual review of genetics* **43**, 95 (2009).
- [46] Rizzuto, R., De Stefani, D., Raffaello, A., and Mammucari, C. Mitochondria as sensors and regulators of calcium signalling. *Nature reviews Molecular cell biology* **13**(9), 566–578 (2012).
- [47] Minczuk, M., Papworth, M. A., Kolasinska, P., Murphy, M. P., and Klug, A. Sequence-specific modification of mitochondrial DNA using a chimeric zinc finger methylase. *Proceedings of the National Academy of Sciences* **103**(52), 19689–19694 (2006).
- [48] Minczuk, M., Papworth, M. A., Miller, J. C., Murphy, M. P., and Klug, A. Development of a single-chain, quasi-dimeric zinc-finger nuclease for the selective degradation of mutated human mitochondrial DNA. *Nucleic acids research* **36**(12), 3926–3938 (2008).
- [49] Gammage, P. A., Rorbach, J., Vincent, A. I., Rebar, E. J., and Minczuk, M. Mitochondrially targeted ZFNs for selective degradation of pathogenic mitochondrial genomes bearing large-scale deletions or point mutations. *EMBO molecular medicine* **6**(4), 458–466 (2014).
- [50] Korzeniewski, B. and Mazat, J.-P. Theoretical studies on the control of oxidative phosphorylation in muscle mitochondria: application to mitochondrial deficiencies. *Biochemical Journal* **319**(1), 143–148 (1996).
- [51] Cree, L. M., Samuels, D. C., de Sousa Lopes, S. C., Rajasimha, H. K., Wonnapijit, P., Mann, J. R., Dahl, H.-H. M., and Chinnery, P. F. A reduction of mitochondrial DNA molecules during embryogenesis explains the rapid segregation of genotypes. *Nature genetics* **40**(2), 249–254 (2008).
- [52] Johnston, I. G., Burgstaller, J. P., Havlicek, V., Kolbe, T., Rülcke, T., Brem, G., Poulton, J., and Jones, N. S. Stochastic modelling, bayesian inference, and new in vivo measurements elucidate the debated mtDNA bottleneck mechanism. *eLife* **4**, e07464 (2015).
- [53] Freyer, C., Cree, L. M., Mourier, A., Stewart, J. B., Koolmeister, C., Milenkovic, D., Wai, T., Floros, V. I., Hagström, E., Chatzidakis, E. E., et al. Variation in germline mtDNA heteroplasmy is determined prenatally but modified during subsequent transmission. *Nature genetics* **44**(11), 1282–1285 (2012).
- [54] Stewart, J. B. and Chinnery, P. F. The dynamics of mitochondrial DNA heteroplasmy: implications for human health and disease. *Nature Reviews Genetics* **16**(9), 530–542 (2015).
- [55] Kaufmann, P., Shanske, S., Hirano, M., DiMauro, S., King, M. P., Koga, Y., and Schon, E. A. Mitochondrial DNA and RNA processing in melas. *Annals of neurology* **40**(2), 172–180 (1996).
- [56] Shoubridge, E. A., Karpatis, G., and Hastings, K. E. Deletion mutants are functionally dominant over wild-type mitochondrial genomes in skeletal muscle fiber segments in mitochondrial disease. *Cell* **62**(1), 43–49 (1990).
- [57] Moraes, C. T., Ricci, E., Petruzzella, V., Shanske, S., DiMauro, S., Schon, E. A., and Bonilla, E. Molecular analysis of the muscle pathology associated with mitochondrial DNA deletions. *Nature genetics* **1**(5), 359–367 (1992).
- [58] Tokunaga, M., Mita, S., Murakami, T., Kumamoto, T., Uchino, M., Nonaka, I., and Ando, M. Single muscle fiber analysis of mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (melas). *Annals of neurology* **35**(4), 413–419 (1994).
- [59] Nicholas, A., Kraytsberg, Y., Guo, X., and Khrapko, K. On the timing and the extent of clonal expansion of mtDNA deletions: evidence from single-molecule PCR. *Experimental neurology* **218**(2), 316–319 (2009).
- [60] Schwarze, S. R., Lee, C. M., Chung, S. S., Roecker, E. B., Weindrich, R., and Aiken, J. M. High levels of mitochondrial DNA deletions in skeletal muscle of old rhesus monkeys. *Mechanisms of ageing and development* **83**(2), 91–101 (1995).
- [61] Reznik, E., Miller, M. L., Şenbabaoğlu, Y., Riaz, N., Sarungbam, J., Tickoo, S. K., Al-Ahmadie, H. A., Lee, W., Seshan, V. E., Hakimi, A. A., et al. Mitochondrial DNA copy number variation across human cancers. *eLife* **5**, e10769 (2016).
- [62] Majamaa-Voltti, K., Peuhkurinen, K., Kortelainen, M.-L., Hassinen, I. E., and Majamaa, K. Cardiac abnormalities in patients with mitochondrial DNA mutation 3243A>G. *BMC cardiovascular disorders* **2**(1), 12 (2002).
- [63] Ciafaloni, E., Ricci, E., Servidei, S., Shanske, S., Silvestri, G., Manfredi, G., Schon, E., and DiMauro, S. Widespread tissue distribution of a tRNA^{leu} (UUR) mutation in the mitochondrial DNA of a patient with melas syndrome. *Neurology* **41**(10), 1663–1663 (1991).
- [64] Anan, R., Nakagawa, M., Miyata, M., Higuchi, I., Nakao, S., Suehara, M., Osame, M., and Tanaka, H. Cardiac involvement in mitochondrial diseases a study on 17 patients with documented mitochondrial DNA defects. *Circulation* **91**(4), 955–961 (1995).
- [65] Jeppesen, T. D., Schwartz, M., Olsen, D. B., and Vissing, J. Oxidative capacity correlates with muscle mutation load in mitochondrial myopathy. *Annals of Neurology* **54**(1), 86–92 (2003).
- [66] Stein, L. R. and Imai, S.-i. The dynamic regulation of NAD metabolism in mitochondria. *Trends in Endocrinology & Metabolism* **23**(9), 420–428 (2012).
- [67] Alano, C. C., Ying, W., and Swanson, R. A. Poly (ADP-ribose) polymerase-1-mediated cell death in astrocytes requires NAD⁺ depletion and mitochondrial permeability transition. *Journal of Biological Chemistry* **279**(18), 18895–18902 (2004).

- [68] Bai, P., Cantó, C., Oudart, H., Brunyánszki, A., Cen, Y., Thomas, C., Yamamoto, H., Huber, A., Kiss, B., Houtkooper, R. H., et al. PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation. *Cell Metabolism* **13**(4), 461–468 (2011).
- [69] Pittelli, M., Felici, R., Pitozzi, V., Giovannelli, L., Bigagli, E., Cialdai, F., Romano, G., Moroni, F., and Chiarugi, A. Pharmacological effects of exogenous nad on mitochondrial bioenergetics, DNA repair, and apoptosis. *Molecular pharmacology* **80**(6), 1136–1146 (2011).
- [70] Korzeniewski, B., Harper, M.-E., and Brand, M. D. Proportional activation coefficients during stimulation of oxidative phosphorylation by lactate and pyruvate or by vasopressin. *Biochimica et Biophysica Acta (BBA)-Bioenergetics* **1229**(3), 315–322 (1995).
- [71] Nobes, C., Hay, W., and Brand, M. The mechanism of stimulation of respiration by fatty acids in isolated hepatocytes. *Journal of Biological Chemistry* **265**(22), 12910–12915 (1990).
- [72] Affourtit, C. and Brand, M. D. Uncoupling protein-2 contributes significantly to high mitochondrial proton leak in INS-1E insulinoma cells and attenuates glucose-stimulated insulin secretion. *Biochemical Journal* **409**(1), 199–204 (2008).
- [73] Lane, N. The problem with mixing mitochondria. *Cell* **151**(2), 246–248 (2012).
- [74] Moreno-Loshuertos, R., Acín-Pérez, R., Fernández-Silva, P., Movilla, N., Pérez-Martos, A., de Cordoba, S. R., Gallardo, M. E., and Enríquez, J. A. Differences in reactive oxygen species production explain the phenotypes associated with common mouse mitochondrial DNA variants. *Nature Genetics* **38**(11), 1261–1268 (2006).
- [75] Michikawa, Y., Mazzucchelli, F., Bresolin, N., Scarlato, G., and Attardi, G. Aging-dependent large accumulation of point mutations in the human mtDNA control region for replication. *Science* **286**(5440), 774–779 (1999).
- [76] Wallace, D. C. Mitochondrial genetics: a paradigm for aging and degenerative diseases? *Science* **256**(5057), 628 (1992).
- [77] Kowald, A. and Klipp, E. Mathematical models of mitochondrial aging and dynamics. *Prog Mol Biol Transl Sci* **127**, 63–92 (2014).
- [78] Yoneda, M., Chomyn, A., Martinuzzi, A., Hurko, O., and Attardi, G. Marked replicative advantage of human mtDNA carrying a point mutation that causes the melas encephalomyopathy. *Proceedings of the National Academy of Sciences* **89**(23), 11164–11168 (1992).
- [79] Kowald, A. and Kirkwood, T. B. Accumulation of defective mitochondria through delayed degradation of damaged organelles and its possible role in the ageing of post-mitotic and dividing cells. *Journal of theoretical biology* **202**(2), 145–160 (2000).
- [80] Twig, G., Elorza, A., Molina, A. J., Mohamed, H., Wikstrom, J. D., Walzer, G., Stiles, L., Haigh, S. E., Katz, S., Las, G., et al. Fission and selective fusion govern mitochondrial segregation and elimination by autophagy. *The EMBO journal* **27**(2), 433–446 (2008).
- [81] Busch, K. B., Kowald, A., and Spelbrink, J. N. Quality matters: how does mitochondrial network dynamics and quality control impact on mtDNA integrity? *Philosophical Transactions of the Royal Society B: Biological Sciences* **369**(1646), 20130442 (2014).
- [82] Poovathingal, S. K., Gruber, J., Halliwell, B., and Gunawan, R. Stochastic drift in mitochondrial DNA point mutations: a novel perspective ex silico. *PLoS computational biology* **5**(11), e1000572 (2009).
- [83] Johnston, I. G. and Jones, N. S. Closed-form stochastic solutions for non-equilibrium dynamics and inheritance of cellular components over many cell divisions. In *Proc. R. Soc. A*, volume 471, 20150050. The Royal Society, (2015).

Supplementary Information

S1 Solutions to the system size expansion

We can describe the mtDNA dynamics analytically using a Master Equation:

$$\begin{aligned} \frac{\partial P_{w,m}}{\partial t} = & \lambda(w-1, m)(w-1)P_{w-1,m} + \mu(w+1)P_{w+1,m} \\ & + \lambda(w, m-1)(m-1)P_{w,m-1} + \mu(m+1)P_{w,m+1} \\ & - [w(\lambda(w, m) + \mu) + m(\lambda(w, m) + \mu)] P_{w,m} \end{aligned} \quad (S1)$$

where $P_{w,m}(t)$ gives the probability of being in state (w, m) . In general, this equation will not be analytically solvable and suitable approximation methods are required. We use Van Kampen's system size expansion to extract a Fokker-Planck equation describing the system, yielding expressions for the means, variances and covariance of w and m (table in Figure 1 of the main text).

A general master equation can be written in the form

$$\dot{p}_n(t) = \Omega \sum_{j=1}^R \left(\prod_{i=1}^N \mathbb{E}^{-S_{ij}} - 1 \right) f_j(n, \Omega) p_n(t) \quad (S2)$$

where Ω is the system volume, R is the number of reactions involved, N is the number of species, $(S)_{ij}$ is the stoichiometry matrix, $n = (n_1, n_2, \dots, n_N)$ gives the number of particles of each species, \mathbb{E} is a raising and lowering operator¹, and $p_n(t)$ is the probability distribution of n at time t . It is often not possible to solve a master equation explicitly, this is only possible in rare cases (the equation *can* be solved analytically for constant or linear rate equations). It is therefore necessary to have approximation methods. The system size expansion, developed by Nico van Kampen, provides a systematic approximation method in the form of an expansion in powers of a small parameter [1]. This parameter, Ω , describes the inverse system size.

To start the construction of the expansion, the state of the system needs to be expressed in terms of a deterministic and stochastic component. Suppose the master equation describes the dynamics of a single species, whose concentration and copy number are denoted by $\phi(t)$ and n . One expects the distribution of n to be centered around $\Omega\phi(t)$ (with Ω the volume (i.e. size) of the system) and have a width of order $\sqrt{n} \propto \sqrt{\Omega}$. This motivates the starting point of the expansion, which is to write

$$n = \Omega\phi(t) + \Omega^{1/2}\xi \quad (S3)$$

where ξ describes the fluctuations around the deterministic solution $\phi(t)$.

All the terms in the master equation can now be expressed in the fluctuation variable ξ , according to the following transformations²

$$\begin{aligned} p_n(t) &= \Pi(\xi, t) \\ \mathbb{E} &\rightarrow 1 + \Omega^{-1/2} \frac{\partial}{\partial \xi} + \frac{1}{2} \Omega^{-1} \frac{\partial^2}{\partial \xi^2} + \dots \\ \dot{p}_n &= \frac{\partial \Pi}{\partial t} - \Omega^{1/2} \sum_{i=1}^N \frac{\partial \phi_i}{\partial t} \frac{\partial \Pi}{\partial \xi_i} \quad (\text{chain rule}) \\ f\left(\frac{n_i}{\Omega}\right) &= f(\phi_i + \Omega^{-1/2}\xi_i) \end{aligned} \quad (S4)$$

which leads to the new equation

$$\begin{aligned} \frac{\partial \Pi}{\partial t} - \Omega^{1/2} \frac{d\phi}{dt} \frac{\partial \Pi}{\partial \xi} &= \Omega \sum_{j=1}^R \left[-\Omega^{-1/2} \sum_{i=1}^N S_{ij} \frac{\partial}{\partial \xi} + \frac{1}{2} \Omega^{-1} \sum_i \sum_k S_{ij} S_{kj} \frac{\partial^2}{\partial \xi_i \partial \xi_k} + O(\Omega^{-3/2}) \right] \\ &\times \left[f_j(\phi) + \Omega^{-1/2} \sum_i \frac{\partial f_j(\phi)}{\partial \phi_i} \xi_i + O(\Omega^{-1}) \right] \Pi(\xi, t) \end{aligned} \quad (S5)$$

¹ Its effect on an arbitrary function $f(\vec{n})$ is given by e.g. $\mathbb{E}_i f(\vec{n}) = f(\vec{n} + e_i)$ and $\mathbb{E}_i^{-1} f(\vec{n}) = f(\vec{n} - e_i)$ (where e_i is a column vector with all zeros and a 1 at entry i). Using a Taylor expansion, the operator can be written as $\mathbb{E}_i = 1 + \frac{\partial}{\partial n_i} + \frac{1}{2!} \frac{\partial^2}{\partial n_i^2} + \dots$.

² \mathbb{E}_i changes n_i into $n_i + 1$, which is equivalent to changing ξ_i into $\xi_i + \Omega^{-1/2}$.

The way to solve this equation is by collecting powers of Ω . The large terms, proportional to $\Omega^{1/2}$, form the macroscopic rate equations. The terms of order Ω^0 form a Fokker-Planck equation, the solution of which is called the Linear Noise Approximation (LNA):

$$\frac{\partial \Pi(\vec{\xi}, t)}{\partial t} = - \sum_{i,j=1}^2 A_{ij} \frac{\partial(\xi_j \Pi)}{\partial \xi_i} + \frac{1}{2} \sum_{i,j=1}^2 B_{ij} \frac{\partial^2 \Pi}{\partial \xi_i \partial \xi_j} \quad (\text{S6})$$

The coefficients A_{ij} and B_{ij} can be found by expanding equation (S5) and are given by

$$\begin{aligned} A_{ij} &= \sum_{k=1}^R S_{ik} \frac{\partial f_k}{\phi_j} \\ B_{ij} &= \sum_{k=1}^R S_{ik} S_{jk} f_k \end{aligned} \quad (\text{S7})$$

For the system we consider, we have

$$S = \begin{pmatrix} 1 & 0 & -1 & 0 \\ 0 & 1 & 0 & -1 \end{pmatrix} \quad (\text{S8})$$

and

$$\begin{aligned} f_1 &= w\lambda(w, m) \\ f_2 &= m\lambda(w, m) \\ f_3 &= w\mu \\ f_4 &= m\mu \end{aligned} \quad (\text{S9})$$

The Fokker-Planck equation can be transformed into a set of coupled ODEs given by

$$\begin{aligned} d_t \langle \xi_w^2 \rangle &= 2A_{11} \langle \xi_w^2 \rangle + 2A_{12} \langle \xi_w \xi_m \rangle + B_{11} \\ d_t \langle \xi_m^2 \rangle &= 2A_{22} \langle \xi_m^2 \rangle + 2A_{21} \langle \xi_w \xi_m \rangle + B_{22} \\ d_t \langle \xi_w \xi_m \rangle &= (A_{11} + A_{22}) \langle \xi_w \xi_m \rangle + A_{12} \langle \xi_m^2 \rangle + A_{21} \langle \xi_w^2 \rangle + B_{12} \end{aligned} \quad (\text{S10})$$

which can be solved to give

$$\begin{aligned} \text{var}(w) &= \frac{\mu w_{ss}^2}{(\partial_m \lambda m_{ss} + \partial_w \lambda w_{ss})^3} \left(2m_{ss} \left(1 + \frac{m_{ss}}{w_{ss}} \right) (\partial_m \lambda)^2 (\partial_m \lambda m_{ss} + \partial_w \lambda w_{ss}) t \right. \\ &\quad - 4(\partial_m \lambda)(\partial_w \lambda) m_{ss} - (\partial_w \lambda)^2 w_{ss} + 3(\partial_m \lambda)^2 m_{ss} \\ &\quad + 4e^{(\partial_m \lambda m_{ss} + \partial_w \lambda w_{ss})t} \{ \partial_m \lambda \partial_w \lambda m_{ss} - (\partial_m \lambda)^2 m_{ss} \} \\ &\quad \left. + e^{2(\partial_m \lambda m_{ss} + \partial_w \lambda w_{ss})t} \{ (\partial_w \lambda)^2 w_{ss} + (\partial_m \lambda)^2 m_{ss} \} \right) \end{aligned} \quad (\text{S11})$$

$$\begin{aligned} \text{var}(m) &= \frac{\mu m_{ss}^2}{(\partial_m \lambda m_{ss} + \partial_w \lambda w_{ss})^3} \left(2w_{ss} \left(1 + \frac{w_{ss}}{m_{ss}} \right) (\partial_w \lambda)^2 (\partial_m \lambda m_{ss} + \partial_w \lambda w_{ss}) t \right. \\ &\quad - 4(\partial_m \lambda)(\partial_w \lambda) w_{ss} - (\partial_m \lambda)^2 m_{ss} + 3(\partial_w \lambda)^2 w_{ss} \\ &\quad + 4e^{(\partial_m \lambda m_{ss} + \partial_w \lambda w_{ss})t} \{ \partial_m \lambda \partial_w \lambda w_{ss} - (\partial_w \lambda)^2 w_{ss} \} \\ &\quad \left. + e^{2(\partial_m \lambda m_{ss} + \partial_w \lambda w_{ss})t} \{ (\partial_w \lambda)^2 w_{ss} + (\partial_m \lambda)^2 m_{ss} \} \right) \end{aligned} \quad (\text{S12})$$

$$\begin{aligned} \text{covar}(w, m) &= \frac{\mu w_{ss} m_{ss}}{(\partial_m \lambda m_{ss} + \partial_w \lambda w_{ss})^3} \left(-2(w_{ss} + m_{ss})(\partial_m \lambda)(\partial_w \lambda)(\partial_m \lambda m_{ss} + \partial_w \lambda w_{ss}) t \right. \\ &\quad + (\partial_w \lambda)^2 w_{ss} + (\partial_m \lambda)^2 m_{ss} - 2(\partial_w \lambda)(\partial_m \lambda)(w_{ss} + m_{ss}) \\ &\quad + 2e^{(\partial_m \lambda m_{ss} + \partial_w \lambda w_{ss})t} \{ (\partial_m \lambda)(\partial_w \lambda)(w_{ss} + m_{ss}) - (\partial_w \lambda)^2 w_{ss} - (\partial_m \lambda)^2 m_{ss} \} \\ &\quad \left. + e^{2(\partial_m \lambda m_{ss} + \partial_w \lambda w_{ss})t} \{ (\partial_w \lambda)^2 w_{ss} + (\partial_m \lambda)^2 m_{ss} \} \right) \end{aligned} \quad (\text{S13})$$

These solutions give the means, variances, and covariance of w and m over time according to the Linear Noise Approximation for a general control $\lambda(w, m)$, assuming a trajectory starting in state (w_{ss}, m_{ss}) . All the partial derivatives are evaluated at the deterministic steady state (w_{ss}, m_{ss}) . The intermediate-time forms of these expressions (when the exponentially decaying terms have died out) are given in Figure 1 in the main text. For very long times (around 1500 days depending on the size the derivative $\partial_w \lambda$ and $\partial_m \lambda$), higher order solutions to the System Size Expansion are required to provide a more accurate description of the dynamics.

The heteroplasmy variance can be derived using a Taylor expansion. If only first order are kept, we obtain: $\text{var}(h) \approx (\frac{\partial h}{\partial w})^2 \sigma_w^2 + (\frac{\partial h}{\partial m})^2 \sigma_m^2 + 2(\frac{\partial h}{\partial w})(\frac{\partial h}{\partial m}) \text{cov}(w, m) = \frac{1}{(w+m)^4} (m^2 \sigma_w^2 + w^2 \sigma_m^2 - 2w m \text{cov}(w, m))$.

S2 Feedback control of a heteroplasmic mtDNA population

Steady states of a linear feedback control When mutant and wildtype mtDNA molecules have identical replication ($\lambda_m = \lambda_w$) and degradation ($\mu_m = \mu_w$) rates, infinitely many steady states exist (i.e. states in which $\lambda = \mu$). These steady states form lines in (w, m) space which can be straight (linear feedback control), form segments of ellipses (quadratic feedback control) or take more complicated forms (Figure S1A). Deterministic trajectories will asymptotically approach the steady state line at a specific point; stochastic trajectories can fluctuate along the line thereby changing heteroplasmy.

A linear feedback control $\lambda(w, m) = c_0 - c_1(w + \delta m)$ gives rise to a straight line of steady states, the slope of which is determined by δ . A small δ means that the steady state line intersects the mutant axis at higher copy number than the wildtype axis, meaning that total copy numbers are higher at $h = 1$ than at $h = 0$. In the extreme case of $\delta = 0$, mutant copy numbers can fluctuate off to infinity, though in practice their numbers will be bounded by space restrictions and resource competition. When $\delta > 1$ copy numbers will decrease as h increases; mutants are now sensed more than wildtypes, which could be caused by e.g. excessive ROS production by mutants (which is then sensed by the cell and incorporated in its feedback function).




Figure S1: **Comparison of different feedback control mechanisms.** Related to Figure 1A-C; **A)** Steady state lines of different kinds of controls are shown in (w, m) space. Line '3', a control only dependent on wildtype species, can give rise to 'runaway dynamics'; mutant copy number can fluctuate off to infinity while wildtype copy number remains stable. **B), C), D)** Here we show three different controls of the form $\lambda(w + \delta m)$ which all have nearly identical wildtype, mutant and heteroplasmy variances. The parameters c_1, d_1, s_1 are set such that the coefficient of variation of the wildtype distribution in the absence of mutants is given by 0.1. Parameters c_0, d_0, s_0 are set such that the wildtype steady state in the absence of mutants is 1000. Initial conditions $w_0 = 919$ and $m_0 = 162$ are used (to give an initial heteroplasmy of $h_0 = 0.15$).

Different forms of control can yield similar mtDNA dynamics. We compared three different forms of feedback control, all of the form $\lambda(w, m) = \lambda(w + \delta m)$: i) $c_0 - c_1(w + \delta m)$, ii) $d_0 + d_1/(w + \delta m)$ and iii) $s_0 - s_1(w + \delta m)^2$ with $c_0, c_1, d_0, d_1, s_0, s_1 > 0$. Figure 1 in the main text shows that wildtype, mutant and heteroplasmy mean are very similar for each of these controls. Here we illustrate that the wildtype, mutant and heteroplasmy variances are also similar (Figure S1B, C, D).

We merely show that these different controls *can* give rise to similar dynamics by parameterising them such that they do. First, we set the variances of each control to be equal in the absence of mutants. From Table 1E it can be seen that the wildtype variance is now completely specified by the mtDNA degradation rate μ , the steady state copy number w_{ss} and the control derivative $\partial_w \lambda(w)$ evaluated at steady state. The control derivatives at steady state for our three different control mechanisms (as defined above) are given by i) $-c_1$, ii) $-d_1/w_{ss}^2$ and iii) $-2s_1 w_{ss}$; these expressions were all set to be -7.21×10^{-6} . This constant value is arbitrary, we chose its value such that at steady state the standard variation of the wildtype distribution is a tenth of its mean value; other choices of this constant will give similar results. We further used $w_{ss} = 1000$, which then fixes the values for c_1, d_1 and s_1 . To ensure that w_{ss} forms the

steady state, we further set $\lambda(w_{ss}) = \mu$ which determines the values of c_0, d_0 and s_0 . Note that it is not surprising that these different controls yield similar dynamics after we have parameterised them to do so; we only want to illustrate these similarities to stress that *which* quantity is being controlled can be more important than *how* it is controlled.

S3 The relationship between resource consumption and energy production

Mitochondrial respiration is a process by which energy from nutrients is converted into (amongst others) ATP. Part of this process involves the pumping of protons across the inner mitochondrial membrane to create an electrochemical potential across the membrane. Energy is released when protons flow back into the matrix and this energy can be used to create ATP. However, the coupling between proton pumping and ATP synthesis is not perfect and protons can leak through the membrane, reducing the efficiency of respiration. An often measured quantity in experimental studies is the mechanistic P/O ratio [2, 3] which refers to the theoretical maximum amount of ATP (P) produced per oxygen (O) reduced by the respiratory chain. The effective P/O ratio is more physiologically relevant and takes into account leak [4].

In our cost function we need to specify how s_i , the power supply measured in ATP (including leak) of a mitochondrion of type i , depends on r_i , a quantity resembling the resource consumption rate of the mitochondrion. For robustness, we use two different equations for $s_i(r_i)$. The first model is based on measurements in isolated mitochondria which found a linear relationship between r_i and s_i (e.g. [5, 6, 4]). We used the data from [5] to fit the parameters of this linear model (Table S1). This data comes from experiments using isolated mitochondria, and it is not clear whether the observations made in isolated mitochondria, without any interactions between the mitochondria and the nucleus or the endoplasmic reticulum, still hold *in vivo*. This is one of the reasons also consider another type of model, as described below.

Our cost function contains a term which penalizes the consumption of resources, meaning that the cheapest state is the one that satisfied demand with the smallest possible resource consumption rate. A linear function $s_i(r_i)$ then implies that for a given demand, the optimal number of mitochondria to have is the minimum number required to satisfy this demand with the mitochondria respiring as fast as they can. However, a minimal number of mitochondria will make the cell less robust to stochastic fluctuations in both mitochondrial copy numbers and demand. Moreover, mitochondria are known to have large spare capacities [7, 8] indicating that in resting state they do not operate near their limits. We therefore expect that there is some extra cellular cost associated with this ‘maximally respiring’ state, causing it to be non-optimal in resting conditions.

This is why we have chosen to use a second model which describes a saturating relationship between r_i and s_i , as shown in Figure S2. Note that we do not claim that mitochondria become less efficient as they respire faster, we impose the saturating shape merely to effectively assign a higher cost to high respiring states. By imposing this saturation, the variable on the y -axis of Figure S2 can be interpreted as an ‘effective energy production’. We will refer to the two models as ‘the linear output model’ and ‘the saturating output model’.

A changing energy production efficiency is not entirely unreasonable, though, because in experiments with isolated mitochondria one usually uses a particular substrate (or a particular combination of substrates) whereas a larger mixture of substrates will be available in the cell, and the relative presence of each substrate may fluctuate over time. The efficiency of respiration depends on the kind of substrate that is used, so it may be possible that at high demand (and high respiration) the substrate of first choice has become limited and another less efficient substrate is used instead. Also, it was suggested that spare capacity can be caused by an increase in substrate entrance in the TCA cycle [9]. This would mean that at high respiration, this high respiration rate is caused by an increase in electron transport chain substrates (e.g. NADH and FADH₂). A ‘push’ to the proton pumping complexes instead of a ‘pull’ at the ATP synthase would lead to an increase in the electrochemical gradient across the membrane and therefore an increase in leak. These arguments are speculative but show that the saturation model may not be unreasonable.

The linear and saturating models are given by the equations:

$$s_w(r_w) = \phi(r_w - \beta) \quad (\text{S14})$$

$$s_w(r_w) = 2 \frac{s_{max}}{1 + e^{-kr_w}} - 1.1s_{max} \quad (\text{S15})$$

where ϕ can be mapped to the effective P/O ratio (here based on the substrates pyruvate and malate), β indicates the respiration rate at zero energy production and therefore specifies the amount of leak, k is the rate at which the saturating model saturates, and s_{max} is an indication of the maximum energy production rate. We have set the parameters k and s_{max} such that the saturating function at first approximately follows the linear function, but then bends away from it at higher respiration rates.

S4 Parameter values for the cost function

Some of our results will be a consequence of the exact structure of our cost function, and might have been different if another type of cost function was used. We would argue, however, that the main elements in our cost function are quite general: terms involving supply, demand, and resource. We aimed at making our cost function simple, and using biologically interpretable parameters. We do not aim to give a detailed kinetic description of the energetic costs involved, but present a simpler description that allows us to compare distinct strategies relative to each other rather than providing absolute costs. We use our cost function as a tool to characterize cost landscapes and begin to explore optimal control strategies.

In the spirit of ‘back-of-the-envelope’ reasoning in biology [10] we seek plausible and interpretable parameter estimates, using both order-of-magnitude estimations and values found in the literature. The parameters with their default values are summarized in Table S1.

The final goal is to obtain a cost for a state with a certain number of mtDNA molecules; we therefore need to express our cost as a cost ‘per mtDNA molecule’. Because the density of mtDNA molecules within the mitochondrial network seems to be roughly constant [11], we assume every mtDNA molecule is associated to a particular amount of mitochondrial volume which we here define as a ‘mitochondrial unit’. All our parameters refer to these mitochondrial units.

S4.1 Mitochondrial energy production and leak: ϕ and β

In our linear model we assume a linear relationship between mitochondrial ATP production rate and mitochondrial oxygen consumption rate, based on experimental data [5, 4, 6]. In [5, 6] measurements show an almost perfect linear relationship between these two quantities. This relationship can also be determined when the effective P/O ratio (the amount of ATP produced per oxygen consumed) is known as a function of the oxygen consumption rate; this also leads to a linear relationship between ATP synthesis rate and oxygen consumption rate [4].

The parameters ϕ and β correspond to the slope and intercept of the linear function, respectively. In [5] this slope was measured to be 2.03 ± 0.13 for isolated pectoralis muscle cell mitochondria in the presence of pyruvate and malate; we have decided to use $\phi = 2$, mainly based on these experiments.

The value of β is an indication of the ‘leakiness’ of the mitochondrion: it represents the rate of oxygen consumption that is required to balance the leakage of protons across the membrane in order to maintain the mitochondrial membrane potential. To obtain a consistent value for β we also use the data presented in [5]. Their measurements find that β is about a tenth of the maximum respiration rate. This maximum respiration rate is obtained by adding high (unlimited) concentrations of ADP; the state of the cell in these conditions is known as state 3_{ADP} . Because state 3_{ADP} does not necessarily correspond to *in vivo* conditions, we define the respiration rate in this state as $r_{\text{max},t}$: the maximum ‘theoretical’ respiration rate. We will fix $r_{\text{max},t} = 1$ and use this to scale our other parameters. This means that our parameter value for β is $\beta = 0.1$.

We stress that though we have based our parameter values here on a specific study, changes in their values will not affect the qualitative structure of our cost function but merely changes the slope and intercept of the linear output function defined in equation (S14).

S4.2 Resource and supply and maintenance cost: r_{max}, r_n and s_n

A cell *in vivo* is unlikely to experience the high concentrations of ADP present in state 3_{ADP} . We therefore set our parameter r_{max} , the physiological maximum respiration rate, to be slightly below $r_{\text{max},t}$: $r_{\text{max}} = 0.95r_{\text{max},t} = 0.95$.

We introduce r_n and s_n as the normal respiration rate and ATP production rate which are present in resting conditions, respectively. Their values will be used to derive other parameter values. Mitochondria have spare capacity, i.e. in normal unstressed conditions they use only part of their maximal oxygen consumption rate (OCR). The amount of spare capacity is usually measured as the fold-change in OCR that occurs after adding FCCP to cells, a mitochondrial uncoupler. Several measurements of the fold-change in OCR are: in the range (2-4)-fold [12], 1.4- to 2.5-fold [9], about 2-fold [7] and about 2.5-fold [8]. The maximum respiration rate when adding FCCP is known as State 3_{FCCP} , and is higher than State 3_{ADP} (see e.g. [13]). We interpret the spare capacity as the ratio $\text{State } 3_{\text{FCCP}}/r_n$, meaning that the ratio r_{max}/r_n is lower than this. We have decided to take $r_{\text{max}}/r_n = 1.5$, meaning that $r_n = r_{\text{max}}/1.5 \approx 0.63$. The value for s_n is now simply $s_n = s_w(r_n) \approx 1.1$.

S4.3 Maintaining, building and degrading: ρ_1 , ρ_2 and ρ_3

The model organism with the most quantitative data on mitochondrial energy budgets is budding yeast, *Saccharomyces cerevisiae*. Reasoning that the scales of biophysical costs of mitochondria are likely comparable across eukaryotes, we first draw from this literature to motivate order-of-magnitude estimates for a range of essential mitochondrial processes. We will later construct parallel estimates using other organisms.

We first focus on estimating the mitochondrial building cost (in ATP) ρ_2 . We provide three distinct estimations and combine them to obtain our final estimate.

For the first estimation we use a list of mitochondrial proteins in yeast [14], and obtain information on turnover rates, abundance (per yeast cell), and lengths (amino acid length) of these proteins by using the *Saccharomyces* Genome Database [15]. We end up with a list of about 200 mitochondrial proteins in yeast *S. cerevisiae*. We incorporate the observation that it takes about 5.2 ATP molecules to elongate a growing peptide chain by adding an amino acid [16], which means that the total synthesis cost of the mitochondrial proteins included in our list is given by $5.2 \sum_i \text{length}_i \text{abundance}_i \approx 2 \times 10^{10}$ ATP per yeast cell. The known number of mitochondrial proteins in *S. cerevisiae* is on the order of 1000 [17]; we will therefore assume that the protein synthesis cost obtained from our protein list corresponds to roughly a fifth of the total mitochondrial protein synthesis cost. We might expect that the proteins best known [14] are the more abundant ones, meaning that our final cost is likely to be an overestimate. We also assume that all of the mitochondrially associated proteins are used exclusively for mitochondrial function. In *E. coli*, the mitochondrial protein synthesis cost represents $\sim 50\%$ of the total mitochondrial synthesis cost (two other major contributors are phospholipid synthesis and RNA synthesis)[16]; we will make the assumption that this observation in *E. coli* holds in mitochondria as well. This brings the total mitochondrial building cost in a single yeast cell to be about 1.9×10^{11} ATP. Assuming 50-100 mtDNA molecules per yeast *S. cerevisiae* cell [18], the building cost associated to a single mtDNA molecule (and therefore the building cost of a mitochondrial unit) is given by $(2 - 4) \times 10^9$ ATP.

For our second estimation we use the total protein weight of a single mitochondrion which was measured to be about 3×10^{-10} mg in rat liver [19], as well as the typical weight of a single protein which is about 5×10^{-17} mg [16]. This means that a mitochondrion contains about 6×10^6 proteins. Using that the typical length of a protein is 300 amino acids [20, 21, 16] together with the 5.2 ATP cost of adding amino acids and the estimation that protein costs represent 50% of the entire building cost, the mitochondrial building cost is estimated to be 2×10^{10} ATP. Note that this cost does not necessarily represent our mitochondrial unit because it is unknown how many mtDNAs a ‘mitochondrion’ corresponded to when measuring its weight in [19].

The third estimation is based on the building cost of an *E. coli*, which is about 10^{10} ATP [16]. Keeping in mind that we want the building cost of a fraction of mitochondrial volume corresponding to a single mtDNA molecule, we need to convert the building cost of an *E. coli* (which has a volume of about $1 \mu\text{m}^3$) to represent our mitochondrial unit. It was estimated that the total mitochondrial network length in yeast *S. cerevisiae* is about $25 \mu\text{m}$ with a total mtDNA copy number of 50-100 [18]. Assuming that the mitochondria form tubules with a constant diameter of 300 nm [22] gives a total mitochondrial volume of about $1.8 \mu\text{m}^3$; another total mitochondrial volume estimate in yeast *S. cerevisiae* is $1.5 \mu\text{m}^3$ [22]. Assuming uniform distributions for the mitochondrial volume ($1.5\text{-}1.8 \mu\text{m}^3$) and mtDNA copy numbers (50-100) leads to a volume of $(2.3 \pm 0.5) \times 10^{-2} \mu\text{m}^3$ per mitochondrial unit. This means that rescaling the *E. coli* building cost gives us an estimate of $(2.3 \pm 0.5) \times 10^{-2} \cdot 10^{10} = (2.3 \pm 0.5) \times 10^8$ ATP to build a single mitochondrial unit. Note that this may represent an overestimation because *E. coli* is a unicellular organism, whereas the mitochondrion is an organelle which cannot survive in isolation [23].

While there are differences in these estimates, arising both from uncertainty and different quantitative lines of reasoning, they together give an overall scale for mitochondrial building cost of around 10^9 ATP. Because in our model we only need a rough estimate of the mitochondrial building cost, we use $\rho_2 = 10^9$ ATP.

We interpret the maintenance cost, denoted by ρ_1 , as the cost in molecules ATP/s corresponding to, for example, maintaining the mitochondrial lipid membranes, importing/exporting proteins, and synthesizing new proteins. To obtain an estimation of ρ_1 , we again use the *Saccharomyces* Genome Database [15]. We can calculate the cost of continuously turning over the ~ 200 proteins in our list (obtained from [14]), leading to $5.2 \sum_i \text{length}_i \text{abundance}_i (\text{degradation rate})_i \approx 6 \times 10^5$ ATP/s per yeast cell. In other words, the maintenance cost per second of our set of mitochondrial proteins is about five orders of magnitude less than their synthesis cost. We therefore assume $\rho_1 = 10^{-5} \rho_2$.

ρ_3 is the most challenging parameter to estimate, as the process of mitochondrial degradation remains poorly characterised. Protein production and biosynthesis costs form the bulk of mitochondrial production requirements, and from cell-wide studies on energy budgets are among the most considerable demands in cell biology. We therefore assume that degradation has lower energy requirements than pro-

duction, and set its upper limit at $\rho_3 = 0.1\rho_2$. Lowering ρ_3 further has little impact on the outcomes of our model.

S4.4 Demand and resource availability: D and R

We want to model two kinds of cells: low copy number cells (1000 wildtype mtDNAs in resting state) and high copy number cells (5000 wildtype mtDNAs in resting state). Denoting this desired number of ‘normal’ mitochondria by w_n , we obtain

$$D = w_n(s_n - \rho_1 - \mu\rho_3 - \lambda\rho_2) \quad (\text{S16})$$

where μ and λ are the degradation and replication rates (per second). This equation says that the overall net output of w_n mitochondria exactly satisfies the demand. Using $w_n = 1000$ and $w_n = 5000$ leads to $D \approx 1055$ and $D \approx 5275$ ATP/s.

The parameter R denotes the maximum rate at which resource can be consumed by all of the mitochondria together and represents a cellular resource availability. In normal resting state the total resource that is consumed is $w_n r_n$, and the resource consumed when these mitochondria respire as fast as they can is $w_n r_{max}$. We then assuming this maximal respiration rate is achieved by using all of the available resources, i.e. $R \approx w_n r_{max}$. It may be, however, that a state of maximum respiration can only be maintained for a short time, and in our cost function we want to describe the ‘steady state cost’ for different states. We therefore assume that $R < w_n r_{max}$ (R now denotes the maximal respiration rate that can be maintained for longer periods of time). We have assumed $R = 0.8w_n r_{max}$ leading to $R = 760$ and $R = 3800$ for $w_n = 1000$ and $w_n = 5000$, respectively.

We note that we base the values for the parameters $s_n = s_w(r_n)$ (and therefore the other parameters) on the linear model, with the idea that these are ‘intrinsic’ mitochondrial parameters, because we have data for this linear model. The saturating model keeps the same intrinsic parameters but is different because of influences from the cell itself.

S4.5 Saturating model parameters: s_{max} and k

We have chosen the parameters of the saturating model described in equation (S15) to approximately match the linear model for low respiration and reach a lower final ATP production rate for higher respiration. The values we used are $s_{max} = 1.54$ and $k = 3.0$.

S4.6 The cost of resource consumption α

The value of α , i.e. the scaling parameter that appears in the cost function given by

$$C(w, m) = |D - S(w, m)| + \alpha(wr_w + mr_m) \quad (\text{S17})$$

is hard to determine. Its value describes the cost of a unit of resource consumption relative to the cost of a unit of ‘energy deficiency’ (the cost of $S(w, m)$ being one energy-unit below D). We estimated that a penalty for resource consumption usage should be about an order-of-magnitude less than the penalty for not-satisfying demand, and have therefore decided to assume $\alpha = 0.1$. We note that the value of α has no influence on the shape of the demand-satisfying region, it changes the relative costs within (and outside of) the region.

S4.7 Mutant parameters: ϵ_1, ϵ_2

In the main text we vary the parameter ϵ_1 , describing the resource uptake rate of mutants relative to wildtypes. Additionally, mutants can be less efficient than wildtypes, producing less energy per resource consumed; we denote this lower mutant efficiency by $\epsilon_2 \in [0, 1]$. Because the number of protons that are pumped across the mitochondrial inner membrane by the electron transport chain complexes for every unit of resource (NADH) that is consumed is fixed, a lower ϵ_2 would have to mean that either i) the mutation has increased proton leak (or other ways of depolarising the membrane), or ii) the mutation has made the ATP synthase dysfunctional. The value of ϵ_2 can be related to the P/O ratio of the mutants relative to that of the wildtypes. Most mtDNA mutations, however, affect the electron transport chain complexes themselves and are therefore likely to reduce the flow of resources through the chain (which would mean a low value for ϵ_1). This is why we assume $\epsilon_2 = 1$ in our main model and only vary the parameter $0 < \epsilon_1 < 1$. For completion, here in the SI we provide a heatmap showing the cost in (w, m) space for various values of ϵ_2 (Figure S3).

S4.8 Parameter units

We can relate our parameter values to actual values, e.g. expressing our demand D in ATP/s. As an example of an ATP demand we use the ATP production rate in unstressed human skin fibroblasts. Assuming that these healthy cells satisfy their demand, their net ATP production rate should equal their ATP demand. The rate of ATP production in skin fibroblasts was estimated to be about 10^9 ATP/s, the large majority of which is supplied by mitochondria [24]. The number of mtDNAs in healthy human skin fibroblasts was measured to be roughly in the range 2400-5200 [25] (the variation in copy number was partly due to variation in ages of the individuals), and we will use the value 4000 as an estimation. Using $w_n = 4000$ we obtain

$$\begin{aligned} 10^9 &= 4000(s_n - \rho_1 - \lambda\rho_2 - \mu\rho_3) \\ &\approx 4000(s_n - \rho_2(10^{-5} + \lambda + 0.1\mu)) \\ &\approx 4000\left(s_n - 10^9\left[10^{-5} + 0.07/(24 \cdot 3600) + 0.1 \cdot 0.07/(24 \cdot 3600)\right]\right) \end{aligned} \quad (\text{S18})$$

Here we used an mtDNA half-life ($T_{1/2}$) of 10 days, giving a degradation rate $\ln(2)/10 \approx 0.07 \text{ day}^{-1}$, and assumed that the cells are in steady state with $\lambda = \mu$. This leads to $s_n \approx 2.6 \times 10^5$ ATP/s meaning that, considering we used $s_n \approx 1.1$, our parameters s_n, D are expressed in units of about 2.6×10^5 ATP/s. This means that, in our units, the parameter values we use for ρ_1, ρ_2 and ρ_3 are $\rho_1 \approx 0.04$, $\rho_2 \approx 3828$, and $\rho_3 \approx 383$.

Par.	Description	default value
D	Mitochondrial energy demand in ATP/s.	5110.7 (high copy number) 1022.1 (low copy number)
R	Maximum rate of resource supplied by the cell to be used by the mitochondria. We use the term ‘resource’ as an amalgamation of different mitochondrial resources, e.g. NAD(H), pyruvate, lactate, succinate, ADP, P_i , and oxygen.	3800 (high copy number) 760 (low copy number)
ϕ	ϕ is related to the effective P/O ratio of a wildtype mtDNA molecule, it represents the slope of the linear relationship between r_w and s_w given in equation (S14)	2.0
β	The fraction of the maximum respiration rate that consists of proton leak, in ‘resource’ per second	0.1
k	Parameter describing the saturation of the saturating model.	3
s_{max}	An indication of the aximum energy supplied by a wildtype mtDNA molecule in the linear model in ATP/s.	1.54
r_{max}	Maximum rate of resource uptake by an mtDNA molecule (i.e. by a mitochondrion containing the mtDNA molecule). This can be interpreted as the maximum flow through the respiratory chain.	0.95
ρ_1	The mitochondrial maintenance cost	0.04 (10^4 ATP/s)
ρ_2	The mitochondrial building cost	3828 (10^9 ATP)
ρ_3	The mitochondrial degradation cost	383 (10^8 ATP)
ϵ_1	The mutant energy production efficiency (the energy produced per unit of resource consumed) relative to that of wildtype mtDNA molecules. A low value of ϵ_1 can be caused by a high proton leak or a deficient ATP synthase.	free parameter, $\epsilon_1 \in [0, 1]$
ϵ_2	The mutant resource uptake rate relative to that of wildtype mtDNA molecules. We will mainly use $\epsilon_1 = 1$ and $\epsilon_2 < 1$ because mtDNA mutations usually affect the proton pumping electron transport chain complexes. A defect in e.g. complex I will reduce its activity and therefore also the rate of consumption of NADH.	free parameter, $\epsilon_2 \in [0, 1]$
α	Scaling parameter in the cost function in front of resource consumption term.	0.1
w_{opt}	The cheapest value for w when $m = 0$, using all of the above parameter values. We have four values for w_{opt} , corresponding to each of the four systems we study.	1524 (saturating low) 7616 (saturating high) 638 (linear low) 3129 (linear high)

Table S1: Parameters used in our cost function with their descriptions

S5 Cost function outputs

Figure S2A shows the behaviour of equations (S14) - (S15) for various parameter values. Note that none of the lines in the figure crosses the origin, because even when no ATP is created, respiration is required

to maintain the gradient which would otherwise be lost due to proton leak. Figure S2B-E shows how resource consumption rate and cost change as the number of mtDNAs changes. Three regimes can be distinguished: 1) there are too few mitochondria present to satisfy demand and they use their maximum possible resource uptake to get their energy production rate as close to D as possible; 2) demand can be satisfied and the cost now only depends on the amount of resource that is used; 3) resource has become limiting and demand cannot be satisfied any more. The main difference between the two models is that in the linear model, when demand is satisfied, the cheapest state is the one with the smallest mtDNA copy number possible whereas the saturating model is cheapest at a higher copy number. This is because mitochondria in the saturating model becomes more efficient as less resources are being consumed.




Figure S2: Relationship between resource consumption and energy output. **A)** Here we show the energy production rate of a single wildtype mitochondrion as a function of its resource consumption rate, as given by equations (S14) - (S15). For the linear model (corresponding to the linear lines in the figure) the parameters ϕ and β are changed by 10%, for the saturating model (corresponding to the saturating curves in the figure) we vary s_{max} and k . The magenta line indicates the value of r_{max} . Our default parameters for the linear model are based on data given in [5] **B)** As w increases, the demand is shared between more mitochondria and each individual mitochondrion can afford to consume resources at a lower rate (the same figure legend applies for figures C, D and E). **C)** The total resource consumption does increase as w increases because the mitochondria need to consume a non-zero amount of resources to produce a net energy output and each mitochondrion comes with a maintenance cost. **D)** The total energy produced by wildtype mitochondria increases when mutants are present because the mutants have a net energy deficit. **E)** When demand is satisfied, the cost increases with w in the linear model, meaning that the minimum cost occurs when mitochondrial copy number attains the minimum number required to satisfy demand (1). In contrast, for the saturating model the cost decreases at first because as the individual resource consumption drops, the energy production efficiency increases. Eventually the cost increases again for similar reasons as in the linear model; minimum cost now occurs when mitochondria are working most efficiently (2). Parameters $\epsilon_1 = 0.1$ and $\epsilon_2 = 1.0$ were used.

In the main text we saw that, in the saturating model, intermediate heteroplasmy values seem to be more expensive than high or low heteroplasmy values. Here we illustrate that in high heteroplasmy regions it is more efficient to increase heteroplasmy even more, whereas in low h conditions it is more efficient to decrease h ; this automatically implies there exists some intermediate heteroplasmy value that is least efficient. Figures S3A, B show the amount of resource consumed by the individual wildtype and mutant mitochondria in four different states. All states have identical total copy numbers ($w + m = 10^4$) but different heteroplasmy values ($h = 0.1, 0.3, 0.7$ and 0.9). All four cases have identical total outputs (equal to the demand). When heteroplasmy increases, the individual resource consumption rates r_w and r_m both increase to compensate for the higher mutant copy number; this is true both in a low- h region (h increases from 0.1 to 0.3, Figure S3A) and a high- h region (h increases from 0.7 to 0.9, Figure S3B). However, the total resource consumption rate does not necessarily increase because the increase in h has caused a number of wildtype mitochondria to become mutants, thereby decreasing their resource usage. Computing the values of the resource consumption rates for the states with $h = 0.1$ and 0.3 , while referring to Figure S3A, gives:

$$\begin{aligned}
 w_1 r_{w_1} &= 9000 r_{w_1} \approx 3227 \\
 m_1 r_{m_1} &= 1000 r_{m_1} \approx 125 \\
 w_2 r_{w_2} &= 7000 r_{w_2} \approx 2981 \\
 m_2 r_{m_2} &= 3000 r_{m_2} \approx 447,
 \end{aligned} \tag{S19}$$




Figure S3: **Intermediate h values require more resources to satisfy demand, but only if mutants consume less resources.** **A)** The resource consumption rates and energy production rates of wildtypes and mutants are shown for two states: $(w_1, m_1, h_1) = (9000, 1000, 0.1)$ and $(w_2, m_2, h_2) = (7000, 3000, 0.3)$. In both cases, the total energy output is equal to the demand. When heteroplasmy is higher ($h = 0.3$), the individual resource consumption rates are higher in order to maintain a constant total energy output. Overall, the state with $h = 0.1$ uses the least resources (Equations S19). $\epsilon_1 = 0.35$ was used. **B)** This figure is similar to Figure (D) but now the two states $(w_1, m_1, h_1) = (3000, 7000, 0.7)$ and $(w_2, m_2, h_2) = (1000, 9000, 0.9)$ are compared. The state with $h = 0.9$ uses the least resources (Equations S20)). **C) + D))** Similar to Figure 2 in the main text, these figures show the cost values in (w, m) space, but now as a function of ϵ_2 (mutant efficiency) instead of ϵ_1 . This time we show the cost in the entire space. The white lines show the region in which demand is satisfied for our default parameter values. Because mutants consume the same amount of resource as wildtypes ($\epsilon_1 = 1$), resource becomes limiting at relatively low values of m compared to when $\epsilon_1 < 1$. Note that intermediate heteroplasms are not less efficient here.

while the states $h = 0.7$ and 0.9 (referring to Figure S3B) give

$$\begin{aligned}
 w_1 r_{w_1} &= 3000 r_{w_1} \approx 1982 \\
 m_1 r_{m_1} &= 7000 r_{m_1} \approx 1618 \\
 w_2 r_{w_2} &= 1000 r_{w_2} \approx 846 \\
 m_2 r_{m_2} &= 9000 r_{m_2} \approx 2665.
 \end{aligned} \tag{S20}$$

Comparing the states with $h = 0.1$ and $h = 0.3$, the *total* rates of resource usage are 3352 and 3428 respectively; the lower heteroplasmy state is more efficient. However, when heteroplasms are higher, the high heteroplasmy state (0.9 rather than 0.7) is most efficient. This effect is due to the non-linearity of Equation S15.

Finally, Figures S3C, D show the cost function as a heatmap in (w, m) space. This figure is similar to Figure 2 in the main text but now we have fixed $\epsilon_1 = 1$ and varied ϵ_2 . Mutants are now less tolerated because they consume just as many resources as wildtypes, but still produce less output. It is now not the case that intermediate heteroplasms are less efficient; *intermediate heteroplasms are only less efficient when $\epsilon_1 < 1$ (mutants consume less resource) and when a saturating output model (Figure S2) is used.* When $\epsilon_1, \epsilon_2 < 1$, it is possible for intermediate heteroplasms to be less efficient but the smaller the value of ϵ_2 , the smaller the range of values of ϵ_1 for which this is true; therefore, the effect of intermediate heteroplasms being less efficient will be most easily observed when the mutant efficiency is close to that of the wildtypes.

S6 Comparison of the cost of different control mechanisms

High costs for not sensing mutants are caused by increases in mean mutant copy number.

In Section 2.3 of the main text we introduced four different feedback controls and compared their cost. These controls are summarized in Table S2 and will be referred to by their labels as provided in the table. In order to compare the controls we imposed two constraints: we demand that, in the absence of mutants, the controls have i) the same deterministic steady state, which is set to be w_{opt} ; and ii) the same steady state variance. It seems a reasonable assumption that any control would be optimal or near optimal in a ‘healthy’ mutant-free state. The goal is to have the controls behaving similarly when $m = 0$ and observe how the dynamics change in the presence of mutants.

As mentioned before (Section S2), when $m = 0$, the wildtype variance is completely specified by the mtDNA degradation rate μ , the steady state copy number w_{opt} and the control derivative $\partial_w \lambda(w)$ evaluated at steady state. We here determine the magnitude of $\partial_w \lambda(w)$ by fixing the parameter α_R in the ‘relaxed replication model’ [26, 27]; its value was suggested to lie between 5 and 17 and here we have used $\alpha_R = 10$. All controls are set to have equal values of $\partial_w \lambda(w)$, and $\lambda(w_{opt}) = \mu$ (with $m = 0$) is used to provide identical steady states (Table S2). Any free parameters left (δ in Control D and γ in control A) are optimized with respect to our cost function; both these optimized parameters specify the relative mutant contribution to the control.

Figure S4 shows the means and variances of the wildtypes, mutants and cost up to ~ 82 years resulting from stochastic simulations. The four controls all started in steady state with $h_0 = 0.15$. We see that the increase in cost for control B is mainly caused by the increase in mean mutant copy number.




Figure S4: **Wildtype, mutant and cost dynamics for four different control strategies.** Dynamics are shown for the four controls A, B, C and D given in TableTab: Section 3 tab SI. Again, we see that the effects of the control are more noticeable in low copy number cells. Parameter are set as given in Table S2; the degradation rate used corresponds to a half-life of 10 days ($\mu \approx 0.07$). Values for w_{opt} are those for the saturating output model at low and high copy number. The free parameters in control A and D (γ and δ) were optimized over initial conditions in the range $h \in [0, 0.2]$. For the optimization the default cost function parameters were used as well as $\epsilon_1 = 0.3$

Optimal linear controls for various mutant pathologies. Figure S5 shows the optimal values for δ in the linear feedback control $\lambda(w, m) = c_0 - c_1(w + \delta m)$ as a function of ϵ_1 . Stochastic simulations

Label	Control	optimal parameters satisfying our two constraints
A	$\lambda(w, m) = \frac{\mu(\alpha_R(w_{opt} - w - \gamma m) + w + \gamma m)}{(w + m)}$	$\alpha_R = 10.0$ γ is optimized
B	$\lambda(w) = c_0 - c_1 w$	$c_1 = \alpha_R \mu / w_{opt}$ $c_0 = \mu + c_1 w_{opt}$
C	$\lambda(w + m) = c_0 - c_1 (w + m)$	$c_1 = -\alpha_R \mu / w_{opt}$ $c_0 = \mu + c_1 w_{opt}$
D	$\lambda(w + \delta m) = c_0 - c_1 (w + \delta m)$	$c_1 = \alpha_R \mu / w_{opt}$ $c_0 = \mu + c_1 w_{opt}$ δ is optimized

Table S2: **Four controls considered with their parameter values.** Two parameters of each control are set by the two constraints we impose. The parameter α_R was proposed to lie in the range 5-17 [26] and here we used $\alpha_R = 10$. The values for δ and γ are found by optimizing our cost function over the steady states corresponding to our initial conditions. We used 50 initial conditions equally spread over the range $h_0 \in [0, 0.2]$. The two values used for w_{opt} are 1524 and 7616 (Table S1).

starting in steady state at either $h_0 = 0.1$ or $h_0 = 0.8$ were performed for 10^4 days. The mean integrated cost over these 10^4 days was evaluated for different values of δ , and the optimal δ values are shown. This was done for both the linear and the saturating model. The general trend is, as was shown for $T = 100$ in the main text, that the lower ϵ_1 the lower the optimal δ .




Figure S5: **At long times and high heteroplasmies, energy sensing control becomes suboptimal.** Related to Figure 3C; The optimal value of δ in a linear feedback control is shown as a function of ϵ_1 . Here we used $T = 10000$ (optimization time) and low copy numbers for both the linear and saturating model. The solid and dashed lines correspond to trajectories starting at $h_0 = 0.1$ and $h_0 = 0.8$, respectively. The less resources the mutants consume (and the less output they therefore produce) the lower their optimal contribution to the control.

S7 Zinc Finger nuclease treatment model

Visualisation of Zinc Finger concentrations during treatment. As explained in the ‘Methods’ section in the main text, we simulate the treatment of cells by mitochondrially targeted Zinc Finger Nucleases (mtZFNs). The concentration of the mtZFNs is modelled by the following equation:

$$[ZFN](t) = \frac{I_0}{\mu_z - b} (e^{-bt} - e^{-\mu_z t}) \quad (\text{S21})$$

where I_0 is the treatment strength (e.g. the initially added mtZFN concentration), b indicates the treatment duration and μ_z is the mtZFN degradation rate. Figure S6A shows this equation for different treatment durations. As we found in the main text, the weaker and longer treatment option leads to larger heteroplasmy shifts.




Figure S6: Zinc Finger Nuclease concentrations for short and long treatments. **A)** Here we show the concentration of mitochondrially targeted Zinc Fingers as modelled by equation (S21). The parameter values for the short and strong treatment ($I_0 = 36, b = 11$) are similar to those found in fitting the model to the data. For the mtZFN degradation rate we used $\mu_z = \log(2)$ (corresponding to a mtZFN half-life of 1 day). **There exists a possibility of increasing heteroplasmy levels through treatment.** **B)** The probability of increasing heteroplasmy above its initial pre-treatment value h_0 , after one round of treatment and recovery, is shown as a function of h_0 and ξ . Cells are initialized with a total copy number of 500. The cross indicates the parameters used in Figure (D). The parameter values for I_0, b and c_1 are set to their fitted values: $(I_0, b, c_1) \approx (39, 20, 3 \times 10^{-4})$. Other parameters used are $\mu_z = \log(2)$ and $\delta = 1$. **C)** Similar to figure (B), but now cells are initialized with a total copy number of 5000; in these large copy number cells stochastic fluctuations in copy number have less effect and the probabilities of exceeding initial heteroplasmy values are smaller compared to Figure (B). **D)** An example of a distribution of post-treatment heteroplasmy values is shown using parameters h_0 and ξ as indicated by the cross in Figure (B). The orange line indicates the value of h_0 (the heteroplasmy that was present before the treatment started).

Heteroplasmy values can increase after nuclease treatments. As mentioned in the Main text in Section 2.3.2, there is a possibility for cellular heteroplasmy to increase after a treatment has been applied. This is true especially if the selectivity of the treatment is low (i.e. ξ is close to 1) and the initial heteroplasmy of a cell is high; in this case treating a cell may even eliminate all wildtype mitochondria, increasing heteroplasmy to 1. To model the extent of this effect we initialize a cell with a given heteroplasmy h_0 , and let it undergo one round of treatment and recovery after which the final heteroplasmy is recorded. This process is repeated to obtain the probability that, given an initial heteroplasmy h_0 , the final heteroplasmy after treatment exceeds h_0 ($P(h_{\text{final}} > h_0 | h_0)$). Figures S6B,C show these probabilities as a function of h_0 and selectivity parameter ξ , for initial mtDNA copy numbers 500 and 5000; the effect-size is larger for low copy number cells. Figure S6D shows an example of the distribution of post-treatment heteroplasmy values. The recovery time used in the simulations is 30 days which is long

enough for the cells to recover their initial copy numbers and short enough for the change in h to be almost completely due to treatment, rather than due to naturally occurring random drifts in heteroplasmy values. Chances of increasing heteroplasmy are highest when h_0 is very high or very low (if h_0 is low the low mutant copy numbers increase the effect of stochastic fluctuations). In the examples shown, when $\xi \leq 0.6$ (i.e. for every mutant that is cleaved, 0.6 wildtypes are cleaved) increases in heteroplasmy are very unlikely to occur.

Details of Figure 5 in the Main text. Our fits to the experimental data [28] were obtained using deterministic (ODE) simulations and least square error. During the treatments a cellular linear feedback control $\lambda(w, m) = c_0 + c_1(w + \delta m)$ is present in order for copy numbers to recover. Figures 5A and B in the Main text show deterministic and stochastic treatment trajectories using parameter values $(I_0, b, \xi, c_1) \approx (40, 12, 0.76, 5 \times 10^{-5})$, which are the fitted parameters obtained when assuming the cells control the quantity $(w + \delta m)$ towards a value of 1000. Parameter c_0 was set to be $c_0 = \mu - c_1(w_0 + \delta m_0) = \mu - c_1 1000$ with $\mu = 0.07$ corresponding to an mtDNA half-life of 10 days. Figure 5C assumes trajectories start in their deterministic steady state. The trajectories shown in Figure 5G have their treatment strengths optimized with respect to our cost function using the saturating model with low copy numbers.

MtZFNs were not able to shift high-heteroplasmy 143B cybrid cells. The possibility of shifting heteroplasmy levels by transfection with mtZFNs was shown in [28, 29]. To further test the capacity of mtZFN to shift heteroplasmy, mtZFN^{2G} (second generation) were transfected into human osteosarcoma 143B cybrid cells bearing 99% m.8993T>G mtDNA, a mutation associated with neuropathy, ataxia, and retinitis pigmentosa (NARP). All methods used are as described in [30]. All possible combinations of mtZFN monomer and control plasmid, including the non-mtDNA targeted PDE12 mtZFN, were transfected. Cells were subjected to FACS 24 hours post-transfection and cells expressing both constructs were sorted, total cellular DNA was extracted and mtDNA heteroplasmy and copy number measured (Figure S7A, B). Cell lines transfected with control plasmids or single mtZFN monomers did not demonstrate any shifts in heteroplasmy or changes in mtDNA copy number. Cells expressing the PDE12 constructs exhibited a depletion of copy number, to around 50% of control, but no shift in heteroplasmy was detected. Cells expressing dual mtZFN targeting the m.8993T>G mutation demonstrated a depletion of mtDNA copy number, to around 10% of control, with a modest shift in wild-type mtDNA heteroplasmy from 1% to 10% when quantified, though the signal-to-noise ratio of these quantifications is poor. However, this shift was not observed when cells were measured 14 days post-transfection, nor at 28 days, though mtDNA copy number had recovered to the control level (Figure S7C, D). These data indicate that mtZFN are not able to shift heteroplasmy in 143B cells bearing 99% m.8993T>G mtDNA. This is consistent with our predictions that it is difficult to decrease mutant mtDNA heteroplasmy in cells with very high initial mutant heteroplasmy. (Section 2.3.2).




Figure S7: Effects of mtZFN^{2G} expression in a 143B cybrid cell line bearing 99% m.8993T>G mtDNA. **A), C)** Last cycle hot PCR RFLP analysis of total cellular DNA extracts from cells transfected with indicated constructs and subjected to FACS sorting 24 hours (A), 14 days (C, left) or 28 days (C, right) post-transfection. PDE12 constructs are non-mtDNA sequence specific mtZFN used as a further control. **B)** qPCR measurement of mtDNA copy number in the same samples as (A). **D)** qPCR measurement of mtDNA copy number in the same samples as (C, left). For Figures (B) and (D) the experiments were performed in quadruplicate; error bars indicate 1 standard deviation.

References

- [1] Van Kampen, N. G. *Stochastic processes in physics and chemistry*, volume 1. Elsevier, (1992).
- [2] Hinkle, P. C. P/O ratios of mitochondrial oxidative phosphorylation. *Biochimica et Biophysica Acta (BBA)-Bioenergetics* **1706**(1), 1–11 (2005).
- [3] Lee, C., Gu, Q., Xiong, Y., Mitchell, R., and Ernster, L. P/O ratios reassessed: mitochondrial P/O ratios consistently exceed 1.5 with succinate and 2.5 with nad-linked substrates. *The FASEB Journal* **10**(2), 345–350 (1996).
- [4] Brand, M. D., Harper, M.-E., and Taylor, H. C. Control of the effective P/O ratio of oxidative phosphorylation in liver mitochondria and hepatocytes. *Biochemical Journal* **291**(3), 739–748 (1993).
- [5] Monternier, P.-A., Marmillot, V., Rouanet, J.-L., and Roussel, D. Mitochondrial phenotypic flexibility enhances energy savings during winter fast in king penguin chicks. *Journal of Experimental Biology* **217**(15), 2691–2697 (2014).
- [6] Salin, K., Roussel, D., Rey, B., and Voituron, Y. David and Goliath: a mitochondrial coupling problem? *Journal of Experimental Zoology Part A: Ecological Genetics and Physiology* **317**(5), 283–293 (2012).
- [7] Yadava, N. and Nicholls, D. G. Spare respiratory capacity rather than oxidative stress regulates glutamate excitotoxicity after partial respiratory inhibition of mitochondrial complex i with rotenone. *The Journal of neuroscience* **27**(27), 7310–7317 (2007).
- [8] Hill, B. G., Dranka, B. P., Zou, L., Chatham, J. C., and Darley-USmar, V. M. Importance of the bioenergetic reserve capacity in response to cardiomyocyte stress induced by 4-hydroxynonenal. *Biochemical Journal* **424**(1), 99–107 (2009).
- [9] Pflieger, J., He, M., and Abdellatif, M. Mitochondrial complex ii is a source of the reserve respiratory capacity that is regulated by metabolic sensors and promotes cell survival. *Cell death & disease* **6**(7), e1835 (2015).
- [10] Johnston, I. G., Rickett, B. C., and Jones, N. S. Explicit tracking of uncertainty increases the power of quantitative rule-of-thumb reasoning in cell biology. *Biophysical journal* **107**(11), 2612–2617 (2014).
- [11] Jajoo, R., Jung, Y., Huh, D., Viana, M. P., Rafelski, S. M., Springer, M., and Paulsson, J. Accurate concentration control of mitochondria and nucleoids. *Science* **351**(6269), 169–172 (2016).
- [12] Sriskanthadevan, S., Jeyaraju, D. V., Chung, T. E., Prabha, S., Xu, W., Skrtic, M., Jhas, B., Hurren, R., Gronda, M., Wang, X., et al. Aml cells have low spare reserve capacity in their respiratory chain that renders them susceptible to oxidative metabolic stress. *Blood* **125**(13), 2120–2130 (2015).
- [13] Nicholls, D. G. Mitochondrial ion circuits. *Essays in biochemistry* **47**, 25–35 (2010).
- [14] Jin, K., Musso, G., Vlasblom, J., Jessulat, M., Deineko, V., Negroni, J., Mosca, R., Malt, R., Nguyen-Tran, D.-H., Aoki, H., et al. Yeast mitochondrial protein–protein interactions reveal diverse complexes and disease-relevant functional relationships. *Journal of proteome research* **14**(2), 1220–1237 (2015).
- [15] Cherry, J. M., Hong, E. L., Amundsen, C., Balakrishnan, R., Binkley, G., Chan, E. T., Christie, K. R., Costanzo, M. C., Dwight, S. S., Engel, S. R., et al. Saccharomyces genome database: the genomics resource of budding yeast. *Nucleic acids research* , D700–D705 (2011).
- [16] Phillips, R., Kondev, J., Theriot, J., and Garcia, H. *Physical biology of the cell*. Garland Science, (2012).
- [17] Herrmann, J. M., Woellhaf, M. W., and Bonnefoy, N. Control of protein synthesis in yeast mitochondria: the concept of translational activators. *Biochimica et Biophysica Acta (BBA)-Molecular Cell Research* **1833**(2), 286–294 (2013).
- [18] Osman, C., Noriega, T. R., Okreglak, V., Fung, J. C., and Walter, P. Integrity of the yeast mitochondrial genome, but not its distribution and inheritance, relies on mitochondrial fission and fusion. *Proceedings of the National Academy of Sciences* **112**(9), E947–E956 (2015).
- [19] Myers, M. W. and Bosmann, H. B. Mitochondrial protein content and enzyme activity of reuber hepatoma h-35. *Cancer research* **34**(8), 1989–1994 (1974).
- [20] Brandt, F., Etchells, S. A., Ortiz, J. O., Elcock, A. H., Hartl, F. U., and Baumeister, W. The native 3d organization of bacterial polysomes. *cell* **136**(2), 261–271 (2009).
- [21] Dill, K. A., Ghosh, K., and Schmit, J. D. Physical limits of cells and proteomes. *Proceedings of the National Academy of Sciences* **108**(44), 17876–17882 (2011).
- [22] Rafelski, S. M., Viana, M. P., Zhang, Y., Chan, Y.-H. M., Thorn, K. S., Yam, P., Fung, J. C., Li, H., Costa, L. d. F., and Marshall, W. F. Mitochondrial network size scaling in budding yeast. *Science* **338**(6108), 822–824 (2012).
- [23] Lane, N. and Martin, W. F. Mitochondria, complexity, and evolutionary deficit spending. *Proceedings of the National Academy of Sciences* **113**(6), E666 (2016).
- [24] Flamholz, A., Phillips, R., and Milo, R. The quantified cell. *Molecular biology of the cell* **25**(22), 3497–3500 (2014).
- [25] Shmookler, R. R. and Goldstein, S. Mitochondrial DNA in mortal and immortal human cells. genome number, integrity, and methylation. *The Journal of biological chemistry* **258**(15), 9078–9085 (1983).

- [26] Chinnery, P. F. and Samuels, D. C. Relaxed replication of mtDNA: a model with implications for the expression of disease. *The American Journal of Human Genetics* **64**(4), 1158–1165 (1999).
- [27] Capps, G. J., Samuels, D. C., and Chinnery, P. F. A model of the nuclear control of mitochondrial DNA replication. *Journal of theoretical biology* **221**(4), 565–583 (2003).
- [28] Gammage, P. A., Gaude, E., Van Haute, L., Rebelo-Guiomar, P., Jackson, C. B., Rorbach, J., Pekalski, M. L., Robinson, A. J., Charpentier, M., Concordet, J.-P., et al. Near-complete elimination of mutant mtDNA by iterative or dynamic dose-controlled treatment with mtZFNs. *Nucleic Acids Research* , 7804–7816 (2016).
- [29] Gammage, P. A., Rorbach, J., Vincent, A. I., Rebar, E. J., and Minczuk, M. Mitochondrially targeted ZFNs for selective degradation of pathogenic mitochondrial genomes bearing large-scale deletions or point mutations. *EMBO molecular medicine* **6**(4), 458–466 (2014).
- [30] Gammage, P. A., Van Haute, L., and Minczuk, M. Engineered mtZFNs for manipulation of human mitochondrial DNA heteroplasmy. *Mitochondrial DNA: Methods and Protocols* , 145–162 (2016).